Use: Labeled indications
- As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia o Hypertriglyceridemia LIPITOR is an HMG-CoA reductase inhibitor (statin) indicated
Full indications and usage US FDA label
1 INDICATIONS AND USAGE LIPITOR is indicated:
- To reduce the risk of: o Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD o MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD o Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD
- As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: o Adults with primary hyperlipidemia. o Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).
- As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).
- As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia o Hypertriglyceridemia LIPITOR is an HMG-CoA reductase inhibitor (statin) indicated (1):
- To reduce the risk of: o Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. o MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD. o Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD.
- As an adjunct to diet to reduce low-density lipoprotein (LDL-C) in: o Adults with primary hyperlipidemia. o Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).
- As an adjunct to other LDL-C-lowering therapies to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia.
- As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia.
Contraindications
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to atorvastatin or any excipient
Contraindications (US label) US FDA label
4 CONTRAINDICATIONS • Acute liver failure or decompensated cirrhosis [see Warnings and Precautions (5.3)] • Hypersensitivity to atorvastatin or any excipients in LIPITOR. Hypersensitivity reactions, including anaphylaxis, angioneurotic edema, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported [see Adverse Reactions (6.2)]. • Acute liver failure or decompensated cirrhosis (4). • Hypersensitivity to atorvastatin or any excipient in LIPITOR (4).
Dosing: Adult
- Hyperlipidemia and cardiovascular risk reduction: Start 10 or 20 mg once daily (40 mg if LDL-C reduction >45% is needed); range 10 to 80 mg once daily
- Take orally once daily with or without food (2.1).
- Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating LIPITOR, and adjust dosage if necessary (2.1).
- Adults (2.2): o Recommended starting dosage is 10 or 20 mg once daily; dosage range is 10 mg to 80 mg once daily. o Patients requiring LDL-C reduction >45% may start at 40 mg once daily.
- Pediatric Patients Aged 10 Years of Age and Older with HeFH: Recommended starting dosage is 10 mg once daily; dosage range is 10 to 20 mg once daily (2.3).
- Pediatric Patients Aged 10 Years of Age and Older with HoFH: Recommended starting dosage is 10 to 20 mg once daily; dosage range is 10 to 80 mg once daily (2.4).
- See full prescribing information for LIPITOR dosage modifications due to drug interactions (2.5).
2.1 Important Dosage Information
2.1 Important Dosage Information
- Take Lipitor orally once daily at any time of the day, with or without food.
- Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating LIPITOR, and adjust the dosage if necessary.
- If a dose is missed, advise patients not to take the missed dose and resume with the next scheduled dose.
2.2 Recommended Dosage in Adult Patients
2.2 Recommended Dosage in Adult Patients The recommended starting dosage of LIPITOR is 10 mg to 20 mg once daily. The dosage range is 10 mg to 80 mg once daily. Patients who require reduction in LDL-C greater than 45% may be started at 40 mg once daily.
2.3 Recommended Dosage in Pediatric Patients 10 Years of Age and Older with HeFH
2.3 Recommended Dosage in Pediatric Patients 10 Years of Age and Older with HeFH The recommended starting dosage of LIPITOR is 10 mg once daily. The dosage range is 10 mg to 20 mg once daily.
2.4 Recommended Dosage in Pediatric Patients 10 Years of Age and Older with HoFH
2.4 Recommended Dosage in Pediatric Patients 10 Years of Age and Older with HoFH The recommended starting dosage of LIPITOR is 10 mg to 20 mg once daily. The dosage range is 10 mg to 80 mg once daily.
2.5 Dosage Modifications Due to Drug Interactions
2.5 Dosage Modifications Due to Drug Interactions Concomitant use of LIPITOR with the following drugs requires dosage modification of LIPITOR [see Warnings and Precautions (5.1) and Drug Interactions (7.1)]. Anti-Viral Medications
- In patients taking saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir, elbasvir plus grazoprevir or letermovir, do not exceed LIPITOR 20 mg once daily.
- In patients taking nelfinavir, do not exceed LIPITOR 40 mg once daily. Select Azole Antifungals or Macrolide Antibiotics
- In patients taking clarithromycin or itraconazole, do not exceed LIPITOR 20 mg once daily. For additional recommendations regarding concomitant use of LIPITOR with other anti-viral medications, azole antifungals or macrolide antibiotics, see Drug Interactions (7.1).
Dosing: Altered kidney function
Atorvastatin needs no dose adjustment in kidney impairment because kidney disease does not change its blood levels (US label). Kidney impairment is a risk factor for myopathy, so muscle symptoms should be watched.
Kidney function measure: Label makes no band distinction.
Show full dosing details
- eGFR ≥60
- No adjustment (label).
- eGFR 30–59
- No adjustment (label). Monitor for myopathy. KDIGO: atorvastatin 20 mg/day is the studied dose in CKD G3a–G5; higher doses not proven safe in CKD.
- eGFR 15–29
- No adjustment (label). Monitor for myopathy. KDIGO: atorvastatin 20 mg/day is the studied dose in CKD G3a–G5; higher doses not proven safe in CKD.
- eGFR <15 (not on dialysis)
- No adjustment (label). Monitor for myopathy. KDIGO: atorvastatin 20 mg/day is the studied dose in CKD G3a–G5; higher doses not proven safe in CKD.
- Hemodialysis (intermittent)
- No dose adjustment (not dialyzed; label). KDIGO: do not start a statin in most patients already on dialysis; continue if already taking one at dialysis initiation.
- Peritoneal dialysis
- No label adjustment; no PD data.
- CRRT
- No data in label.
- Dialyzable? Not expected to be significantly removed by hemodialysis (label).
- Monitoring Muscle symptoms (myopathy, rhabdomyolysis); renal impairment is a risk factor (label).
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- No pediatric kidney data; no change expected (adult label has no kidney adjustment). Specialist input.
- eGFR 30–59
- No pediatric kidney data; no change expected (adult label has no kidney adjustment). Specialist input.
- eGFR 15–29
- No pediatric kidney data; no change expected (adult label has no kidney adjustment). Specialist input.
- eGFR <15 (not on dialysis)
- No pediatric kidney data; no change expected (adult label has no kidney adjustment). Specialist input.
- Hemodialysis (intermittent)
- No pediatric data.
- Peritoneal dialysis
- No pediatric data.
- CRRT
- No pediatric data.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Renal impairment US FDA label
8.6 Renal Impairment Renal impairment is a risk factor for myopathy and rhabdomyolysis. Monitor all patients with renal impairment for development of myopathy. Renal impairment does not affect the plasma concentrations of LIPITOR, therefore there is no dosage adjustment in patients with renal impairment [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].
Renal Impairment Renal disease has no influence on the plasma concentrations or LDL-C reduction of LIPITOR [see Use in Specific Populations (8.6)]. While studies have not been conducted in patients with end-stage renal disease, hemodialysis is not expected to significantly enhance clearance of LIPITOR since the drug is extensively bound to plasma proteins.
Dosing: Hepatic impairment
8.7 Hepatic Impairment In patients with chronic alcoholic liver disease, plasma concentrations of LIPITOR are markedly increased. Cmax and AUC are each 4-fold greater in patients with Childs-Pugh A disease. Cmax and AUC are approximately 16-fold and 11-fold increased, respectively, in patients with Childs-Pugh B disease. LIPITOR is contraindicated in patients with acute liver failure or decompensated cirrhosis [see Contraindications (4)].
US FDA labelDosing: Pediatric
- Approved ages
- Heterozygous familial hypercholesterolemia (HeFH) and homozygous FH (HoFH): 10 years and older. Not established under 10 years or for other hyperlipidemias (label).
- Usual dose
- HeFH: 10 mg once daily, range 10 to 20 mg. HoFH: 10 to 20 mg once daily, range 10 to 80 mg (label gives fixed doses, not mg/kg).
- Maximum dose
- HeFH 20 mg/day; HoFH 80 mg/day (label).
- Neonates
- Neonates: not established.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of LIPITOR as an adjunct to diet to reduce LDL-C have been established pediatric patients 10 years of age and older with HeFH. Use of LIPITOR for this indication is based on a double-blind, placebo-controlled clinical trial in 187 pediatric patients 10 years of age and older with HeFH.
In this limited controlled trial, there was no significant effect on growth or sexual maturation in the males or females or on menstrual cycle length in females. The safety and effectiveness of LIPITOR as an adjunct to other LDL-C-lowering therapies to reduce LDL-C have been established pediatric patients 10 years of age and older with HoFH.
Use of LIPITOR for this indication is based on a trial without a concurrent control group in 8 pediatric patients 10 years of age and older with HoFH [see Clinical Studies (14)]. The safety and effectiveness of LIPITOR have not been established in pediatric patients younger than 10 years of age with HeFH or HoFH, or in pediatric patients with other types of hyperlipidemia (other than HeFH or HoFH).
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Of the total number of LIPITOR-treated patients in clinical trials, 15,813 (40%) were ≥65 years old and 2,800 (7%) were ≥75 years old. No overall differences in safety or effectiveness were observed between these patients and younger patients. Advanced age (≥65 years) is a risk factor for LIPITOR-associated myopathy and rhabdomyolysis.
Dose selection for an elderly patient should be cautious, recognizing the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of myopathy. Monitor geriatric patients receiving LIPITOR for the increased risk of myopathy [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].
Dosage forms
Philippines
- Film-coated tablet: 5 mg/10 mg, 10 mg, 20 mg, 40 mg, 80 mg
- Tablet: 10 mg, 20 mg, 40 mg, 80 mg
- Fiim-coated tablet: 40 mg
- Film-coated: 10 mg
Registered products in the Philippines
458 products registered with the Food and Drug Administration (FDA) Philippines list Atorvastatin as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Atorvastation (As Calcium) (2 products). Products registered under these spellings are included in the table and marked.
All registered products458
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
2rvazAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 16's, 24's, and 80's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DR-XY44284 | Feb 9, 2037 | |
AdivastAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma, Incorporated | DR-XY38984 | Jan 26, 2031 | |
AdivastAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 24's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma, Incorporated | DR-XY38508 | Sep 15, 2031 | |
AstatAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Medisure Laboratories Pakistan (Pvt.) LimitedPakistan | Accesspoint International Trading Inc. | DRP-6127 | May 5, 2031 | |
AstatAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Medisure Laboratories Pakistan (Pvt.) LimitedPakistan | Accesspoint International Trading Inc. | DRP-6126 | Feb 9, 2037 | |
AstorvAtorvastatin(As Calcium) | 20 mg Film-Coated TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | 777 Red Pharma Inc.Importer: Philgen Pharmaceuticals Inc. | DRP-2778-05 | Jul 14, 2027 | |
AstorvAtorvastatin(As Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | 777 Red Pharma Inc.Importer: Philgen Pharmaceuticals Inc.Trader: N.A. | DRP-5224-01 | Jun 28, 2027 | |
AtocardAtorvastatin (as Calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | — | DRP-7663 | Jan 22, 2030 | |
AtocardAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 24's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | — | DRP-7804 | May 12, 2030 | |
AtocureAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's and 200's); Alu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories, Inc.Philippines | Jaac Healthline Marketing | DRP-6339-10 | Sep 11, 2031 | |
AtocureAtorvastatin (as Calcium) | 80 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Jaac Healthline Marketing | DRP-6341-09 | Sep 11, 2030 | |
Atoget 20Atorvastatin (as calcium) | 20 mg Film Coated TabletAlu-Amber PVC Blister pack (Box of 10's) | RxVAT-exempt | Sain Medicaments Pvt. Ltd.India | 2MG Incorporated | DRP-18408 | Jul 6, 2031 | |
AtopitarAtorvastatin (as Calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's ( Box of 20's) | RxVAT-exempt | GEOFMAN PHARMACEUTICALSPakistan | SAHAR INTERNATIONAL TRADING INC. | DR-XY33467 | Jun 7, 2027 | |
AtopitarAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 20's) | RxVAT-exempt | Geofman PharmaceuticalsPakistan | Sahar International Trading, Inc. | DR-XY35745 | Apr 27, 2029 | |
AtopitarAtorvastatin (as calcium) | 40 mg Film - Coated TabletAlu/Alu Blister Pack x 10's (Box of 20's) | RxVAT-exempt | Geofman PharmaceuticalsPakistan | Sahar International Trading Inc. | DRP-2623 | Oct 14, 2029 | |
Ator-10Atorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-5614 | Mar 19, 2029 | |
Ator-20Atorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-7120 | Mar 19, 2029 | |
Ator-40Atorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 8's Box of 24's | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-7054 | Mar 19, 2029 | |
AtorbellaAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 60's, 90's and 100's) | RxVAT-exempt | Flourish PharmaIndia | Speed Med Pharmaceuticals Inc.Importer: Biophil Medical Equipment and Supplies Trading | DRP-17462 | Jun 23, 2031 | |
AtorbellaAtorvastatin (As Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 60's, 90's and 100's) | RxVAT-exempt | Flourish PharmaIndia | Speed Med Pharmaceuticals Inc.Importer: Biophil Medical Equipment and Supplies Trading | DRP-17463 | Jun 23, 2031 | |
AtorbellaAtorvastatin (As Calcium) | 80 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Flourish PharmaIndia | Biophil Medical Equipment and Suppies Trading | DRP-17464 | May 21, 2031 | |
AtorbetAtorvastatin | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 50’s and 100’s) | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | Better Option Pharmaceuticals, Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-1721-02 | Aug 25, 2029 | |
AtorbetAtorvastatin | 20 mg Film-Coated TabletAlu-Alu Blister Pack x 10’s Box of 50’s and 100’s | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | Better Option Pharmaceuticals, Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-1720-02 | Aug 25, 2029 | |
AtorbetAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10‘s (Box of 50’s & 100’s) | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | Better Option Pharmaceuticals, Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-2254-01 | Mar 12, 2031 | |
AtorcadAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Pharma Dynamic, Inc. | DRP-5155-02 | Sep 2, 2028 | |
ATORCURAAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister pack x 10’s (Box of 100’s) | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | Rvm Pharma & Medical Supplies DistributionImporter: Suhitas Pharmaceuticals Inc. | DRP- 9837-03 | Jun 23, 2031 | |
AtorcuraAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100's) | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | RVM Pharma & Medical Supplies DistributionImporter: Suhitas Pharmaceuticals Inc. | DRP-2254-07 | Jun 9, 2031 | |
AtorenAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Philippine Home Pharmaceuticals | DR-XY44031 | Jan 12, 2030 | |
Atorfil 20Atorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Healer’s Lab (Unit II)India | PH Phil Asia Medica Co.Importer: Pharmakon Biotec Inc. | DRP-13973-05 | May 26, 2028 | |
AtorgardAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Solvang Pharmaceuticals, Inc.Trader: Dr. Zen’s Research, Inc. | DRP-7550 | May 14, 2030 | |
AtorgardAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Solvang Pharmaceuticals, Inc.Trader: Dr. Zen’s Research, Inc. | DRP-8345 | Jan 23, 2030 | |
AtorgardAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 24's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Solvang Pharmaceuticals, Inc.Trader: Dr. Zen’s Research, Inc. | DRP-7551 | May 12, 2030 | |
AtorgenAtorvastatin (as Calcium) | 10 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 40's (Box of 40's, 120's and 200's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | EBA GENERISCH TRADING INC. | DRP-5880-01 | Sep 9, 2029 | |
AtorgenAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generisch Trading Inc. | DRP-6340-01 | Sep 26, 2031 | |
AtorgenAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generisch Trading Inc. | DRP-6339-01 | Sep 22, 2031 | |
AtorgenAtorvastatin (as Calcium) | 80 mg Film-Coated TabletAlu PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generisch Trading Inc. | DRP-16342-02 | Feb 12, 2030 | |
AtorgenAtorvastatin (as Calcium) | 80 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generisch Trading Inc. | DRP-6341-01 | Sep 29, 2031 | |
Atorgold-10Atorvastatin (as Calcium) | 10 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 40's (Box of 40's; 120's and 200's); Alu/Opaque White PVC Blister Pack x 20's (Box of 100's); Alu/Opaque White PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Brilliantmeed, Inc. | DRP-5880-09 | Sep 9, 2029 | |
ATORGOLD-20Atorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 20's (Box of 100's and 200's); Alu/Opaque White PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Brilliantmeed, Inc. | DRP-6340-09 | Sep 11, 2030 | |
Atorgold-40Atorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's and 200's); Alu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories, Inc.Philippines | Brilliantmeed, Inc. | DRP-6339-09 | Sep 11, 2030 | |
Atorgold-80Atorvastatin (as Calcium) | 80 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's and 200's); Alu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Brilliantmeed, Inc. | DRP-6341-08 | Sep 11, 2030 | |
Atorgrand-20Atorvastatin (as calcium) | 20 mg Film-Coated TabletAlu / Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Healer's Lab (Unit II)India | Grandis Pharma IncorporatedImporter: Pharmakon Biotec Inc. | DRP-13973-04 | May 26, 2028 | |
Atorimax-20Atorvastatin Calcium | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Healer's Lab (Unit II)India | Pharmakon Biotec Inc. | DRP-13973 | May 26, 2028 | |
Atorimax-40Atorvastatin (as calcium trihydrate) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Healer's Lab (Unit II)India | Pharmakon Biotec Inc. | DRP-15961 | Oct 4, 2029 | |
Atorimax-80Atorvastatin (as calcium trihydrate) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Healer's Lab (Unit II)India | Pharmakon Biotec, Inc. | DRP-15046 | Jul 3, 2029 | |
Atorix-20Atorvastatin (as calcium trihydrate) | 20 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Healer's Lab (Unit II)India | Teramedix Pharma Trading Inc.Trader: Sarva Pharmaceuticals Pvt. Ltd. | DRP-14082 | Jun 16, 2028 | |
AtorleeAtorvastatin | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | GMX SolutionsTrader: D.B. Manix International, Inc. | DRP-8366 | Dec 17, 2029 | |
Atorlipids 20Atorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-10747-03 | Aug 17, 2037 | |
Atorlipids 40Atorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s and 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-3109-11 | Jul 12, 2029 | |
AtormaxAtorvastatin (as Calcium) | 20mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Flamingo Pharmaceuticals Ltd.India | Excelcare, Inc.Importer: Hexagon Pharmaceuticals | DRP-2383-02 | Apr 17, 2029 | |
Atormed-10Atorvastatin (As Calcium Trihydrate) | 10mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | ACME Formulations Pvt. Ltd.India | Medinova Pharmaceutical, Inc. | DRP-12225 | Jul 12, 2027 | |
Atormed-20Atorvastatin(as Calcium Trihydrate) | 20mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | ACME Formulations Pvt. Ltd.India | Medinova Pharmaceutical, Inc. | DRP-12155 | Jun 22, 2027 | |
AtorNavAtorvastatin | 20 mg Film-Coated TabletClear PVC / Alu foil blister pack x 10's (Box of 100's) | RxVAT-exempt | Scheele Laboratories Phils., Inc.Philippines | JN Carlo Pharmaceuticals | DRP-7530-03 | Dec 1, 2027 | |
AtorNavAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu / Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Scheele Laboratories Phils., Inc.Philippines | JN Carlo Pharmaceuticals Distributor | DRP-8593-01 | Dec 20, 2029 | |
AtorpelAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu / Opaque White PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Errapel Pharmed Corp. | DRP-6340-05 | Sep 19, 2031 | |
AtorpelAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Errapel Pharmed Corp. | DRP-6339-05 | Oct 20, 2031 | |
AtorpelAtorvastatin (as Calcium) | 80 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Errapel Pharmed Corp. | DRP-6341-05 | Oct 30, 2031 | |
AtorphilAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Phil Asia Pharma, Inc.Importer: Ambica International Corporation | DRP-3109-02 | Jul 12, 2029 | |
Atorpina-20Atorvastatin (as calcium trihydrate) | 20 mg Film-Coated TabletAlu-Alu blister pack x 10's (Box of 30's and 60's) | RxVAT-exempt | Pinnacle Life Science Pvt. Ltd.India | Despina Pharma Inc. | DRP-15744 | Sep 11, 2029 | |
Atorpina-40Atorvastatin (as calcium trihydrate) | 40 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's and 60's) | RxVAT-exempt | Pinnacle Life Science Pvt. Ltd.India | Despina Pharma Inc. | DRP-15743 | Sep 11, 2029 | |
AtorproAtorvastatin (as Calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Transcend Phils., Inc. | DRP-7519 | Jan 22, 2030 | |
AtorproAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Transcend Phils., Inc. | DRP-7520 | Jan 12, 2030 | |
AtorproAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 24's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Transcend Phils., Inc. | DRP-7521 | May 12, 2030 | |
AtorsaphAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 20's); Alu/Clear PVC Blister Pack x 10's (Box of 30's); Alu/Clear PVC Blister Pack x 10's (Box of 60's); Alu/Clear PVC Blister Pack x 10's (Box of 90's); Alu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | SAPPHIRE LIFESCIENCES PVT. LTDIndia | NELPA LIFESCIENCES, INC. | DRP-4470 | Jun 13, 2028 | |
AtorsaphAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 20's | RxVAT-exempt | SAPPHIRE LIFESCIENCES PVT. LTDIndia | NELPA LIFESCIENCES, INC. | DRP-5211 | Mar 5, 2029 | |
Atorsaph-40Atorvastatin (As Calcium) | 40 mg Film-coated TabletAlu Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Sapphire Lifesciences Pvt. LtdIndia | Nelpa Lifesciences, Inc. | DRP-11000 | Dec 31, 2026 | |
Atorsaph-80Atorvastatin (as calcium) | 80 mg Film-Coated TabletAlu Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc. | DRP-10995 | Nov 5, 2030 | |
Atorsave-10Atorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Medisky PharmaceuticalsIndia | Savelink Pharma and Trading Co.Importer: Aglobal Care, Inc. | DRP-15640-02 | Aug 14, 2029 | |
Atorsave-20Atorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Medisky PharmaceuticalsIndia | Savelink Pharma and Trading Co.Importer: Aglobal Care, Inc. | DRP-15641-01 | Aug 14, 2029 | |
Atorsave-40Atorvastatin (as calcium) | 40 mg Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Medisky PharmaceuticalsIndia | Savelink Pharma And Trading Co.Importer: Aglobal Care, Inc. | DRP-15543-01 | Aug 7, 2029 | |
AtorschwartzAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Medcare PharmaceuticalsImporter: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-5137-05 | Feb 13, 2029 | |
Atorschwartz 10Atorvastatin (as Calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Medcare PharmaceuticalsImporter: Ambica International Corporation | DRP-3123-05 | Jul 12, 2029 | |
Atorschwartz 20Atorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Medcare PharmaceuticalsImporter: Ambica International Corporation | DRP-4879-07 | Nov 7, 2028 | |
Atorschwartz 80Atorvastatin (as calcium) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Medcare PharmaceuticalsImporter: Ambica International Corporation | DRP-10749-06 | Nov 15, 2031 | |
Atorseth-40Atorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10‘s (Box of 100’s) | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | 999 Seth Pharmaceutical Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-2254-05 | Mar 15, 2031 | |
Atorsky-20Atorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's and 30's) | RxVAT-exempt | Ratnatris Pharmaceuticals Private LimitedIndia | Skymed Pharma DistributorImporter: Medinova Pharmaceutical Inc | DRP-15714-04 | Sep 6, 2029 | |
AtorstanAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack X 8's (Box of 40's) | RxVAT-exempt | J.M. Tolmann Laboratories, Inc.Philippines | Gold Life Distribution Phils. Inc. | DRP-3175-09 | Jan 4, 2030 | |
Atorvacor-10Atorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s Box of 100’s | RxVAT-exempt | Akums Drugs & Pharmaceuticals, Inc.India | Diafarm Inc.Trader: Unosource Pharma Limited | DRP-2997 | May 26, 2029 | |
Atorvanov 40Atorvastatin (as calcium) | 40 mg Film-Coated Tablet | RxVAT-exempt | S Kant Healthcare Ltd.India | Medinova Pharmaceutical Inc. | DRP-17691 | Feb 18, 2032 | |
Atorvanov 80Atorvastatin (as calcium) | 80 mg Film-Coated Tablet | RxVAT-exempt | S Kant Healthcare Ltd.India | Medinova Pharmaceutical Inc | DRP-17686 | Feb 16, 2032 | |
AtorvasAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 30's) | RxVAT-exempt | Bal Pharma LimitedIndia | Euroasia Pharmaceuticals, Inc.Importer: Pharmakon Biotec Inc. | DRP-5128-01 | Feb 12, 2029 | |
Atorvas 40Atorvastatin (as calcium) | 40 mg Film coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | EuroAsia Pharmaceuticals, Inc.Trader: Tunic Healthcare | DRP-10107 | Apr 21, 2031 | |
Atorvast 20Atorvastatin(As Calcium) | 20 mg Film-Coated TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | The Generics Pharmacy, Inc.Importer: Philgen Pharmaceuticals Inc. | DRP-2778-03 | Jul 14, 2027 | |
Atorvast-NatrapharmAtorvastatin (as calcium propylene glycol solvate) | 20mg Film-Coated tabletAlu/Alu Blister Pack x 10's Box of 10's; Alu/Alu Blister Pack x 10's Box of 100's | RxVAT-exempt | Apotex, Inc.Canada | Importer: Natrapharm, Inc. | DR-XY40121 | Oct 4, 2029 | |
Atorvast-NatrapharmAtorvastatin (as calcium propylene glycol solvate) | 40 mg Film-Coated tabletAlu/Alu Blister Pack x 10's (Box of 10's); Alu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Apotex, Inc.Canada | Importer: Natrapharm, Inc. | DR-XY40120 | Oct 4, 2029 | |
Atorvast-NatrapharmAtorvastatin (as calcium propylene glycol solvate) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's); Alu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Apotex Inc.Canada | Importer: Natrapharm, Inc. | DR-XY40119 | Oct 4, 2029 | |
Atorvax10Atorvastatin (as Calcium Trihydrate) | 10 mg Film-Coated TabletAlu-Alu Blister pack x 10's (Box of 100's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises, Inc. | DRP-18495 | Jul 22, 2031 | |
Atorvax20Atorvastatin (as Calcium Trihydrate) | 20 mg Film-Coated TabletAlu-Alu Blister pack x 10's (Box of 100's) | RxVAT-exempt | Globela Pharma Pvt. Ltd.India | AMB HK Enterprises, Inc. | DRP-18494 | Jul 22, 2031 | |
Atorvax40Atorvastatin (as Calcium Trihydrate) | 40 mg Film-Coated TabletAlu-Alu Blister pack x 10's (Box of 100's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises, Inc. | DRP-18493 | Jul 22, 2031 | |
Atorvax80Atorvastatin (as Calcium Trihydrate) | 80 mg Film-Coated TabletAlu-Alu Blister pack x 10's (Box of 100's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises, Inc. | DRP-18491 | Jul 22, 2031 | |
Atorvex-10Atorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's and 30's) | RxVAT-exempt | Ratnaris Pharmaceuticals Private LimitedIndia | Reta DrugImporter: Medinova Pharmaceutical Inc. | DRP-15715-01 | Sep 5, 2029 | |
Atorvex-10Atorvastatin (as Calcium Trihydrate) | 10mg FIlm-CoatedAlu-Alu Blister Pack x 10's (Box of 30's; Box of 100's) | RxVAT-exempt | ACME Formulations Pvt. Ltd.India | Reta DrugImporter: Medinova Pharmaceutical Inc. | DRP-12225-01 | Jul 12, 2027 | |
Atorvex-20Atorvastatin (as Calcium Trihydrate) | 20 mg Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 30's. Box of 100's) | RxVAT-exempt | Acme Formulation Pvt. Ltd.India | Reta DrugImporter: Medinova Pharmaceutical Inc. | DRP-12155-02 | Jun 22, 2027 | |
Atorvex-20Atorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's; Box of 100's) | RxVAT-exempt | Ratnatris Pharmaceuticals Private LimitedIndia | Reta DrugImporter: Medinova Pharmaceutical Inc. | DRP-15714-02 | Sep 6, 2029 | |
Atorviq 40Atorvastatin (as calcium trihydrate) | 40 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Healer’s Lab (Unit II)India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-15961-06 | Oct 4, 2029 | |
AtorwinAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 28's and 30's) | RxVAT-exempt | ZENTIVA, K.S.Czech Republic | Importer: SANOFI-AVENTIS PHILIPPINES, INC | DRP-7946 | Aug 8, 2028 | |
AtorwinAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | ZENTIVA, K.S.Czech Republic | Importer: SANOFI-AVENTIS PHILIPPINES, INC | DRP-7947 | Aug 8, 2028 | |
AtorwinAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Saneca Pharmaceuticals A.S.Slovakia | Importer: sanofi-aventis Philippines, Inc. | DRP-2492 | Sep 27, 2030 | |
AtorwinAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | ZENTIVA, K.S.Czech Republic | Importer: SANOFI-AVENTIS PHILIPPINES, INC | DRP-7948 | Aug 8, 2028 | |
Atosar-10Atorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 50’s & 100’s) | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | Suhitas Pharmaceuticals Inc. | DRP-9838 | Jun 23, 2031 | |
Atosar-20Atorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 50’s & 100’s) | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | Suhitas Pharmaceuticals Inc. | DRP-9837 | Jun 23, 2031 | |
AtovasAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Vitalink Health Products, Inc. | DR-XY38983 | Jan 26, 2031 | |
AtovasAtorvastatin (as calcium) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 24's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Vitalink Health Products, Inc. | DR-XY37436 | Feb 9, 2030 | |
Atozan-10Atorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 40's (Box of 40's, 120's & 200's); Alu/Opaque White PVC Blister Pack x 20's (Box of 100's); Alu/Opaque White PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Triple 888 Medical And Pharma Inc. | DRP-5880-07 | Sep 9, 2029 | |
Atozan-20Atorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories, Inc.Philippines | Tripple 888 Medical and Pharma Inc. | DRP-6340-08 | Sep 11, 2030 | |
Atozan-40Atorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's and 200's); Alu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories, IncPhilippines | Triple 888 Medical And Pharma Inc. | DRP-6339-07 | Sep 11, 2030 | |
AtrhosAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s and 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-3109-12 | Jul 12, 2029 | |
AtrodipexAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc. | DRP-11000-01 | Dec 31, 2026 | |
AtrodipexAtorvastatin (as calcium) | 80 mg Film-Coated TabletAlu Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc. | DRP-10995-01 | Dec 31, 2026 | |
Atropen-40Atorvastatin (as calcium) | 40 mg FiIm-Coated TabletAlu/Alu Blister x 10's (Box of 100's) | RxVAT-exempt | Gpax Pharmaceuticals Private Ltd.India | A. Pendragon International Distribution OpcImporter: Khriz Pharma Trading Inc. | DRP-13270-01 | Feb 8, 2028 | |
ATV 10Atorvastatin (as Calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Delta Pharma Ltd.Bangladesh | Importer: Biomed Pharma Inc. | DR-XY40506 | Jan 6, 2027 | |
ATV 40Atorvastatin(calcium) | 40 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Delta Pharma Ltd.Bangladesh | Biomed Pharma Inc. | DRP-15970 | Oct 7, 2029 | |
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Amherst Laboratories Inc.Philippines | Trader: UNILAB, Inc. | DR-XY44383 | Sep 30, 2029 | ||
AvamaxAtorvastatin (As Calcium trihydrate) | 10 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 100's) | RxVAT-exempt | PT Darya-Varia Laboratoria, Tbk.Indonesia | UNILAB, Inc. | DRP-12136 | Jun 22, 2027 | |
AvamaxAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Ranbaxy (Malaysia) Sdn. Bhd.Malaysia | UNILAB, INC.Importer: Ritemed Phils., Inc. | DRP-1233-02 | Feb 2, 2029 | |
AvamaxAtorvastatin (as Calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 100's | RxVAT-exempt | Lek Pharmaceuticals D.D.Slovenia | Unilab, Inc.Importer: Sandoz Philippines Corporation | DRP-2278-01 | Aug 13, 2029 | |
20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Amherst Laboratories IncPhilippines | Trader: UNILAB, Inc. | DR-XY44382 | Sep 30, 2029 | ||
AvamaxAtorvastatin (As Calcium trihydrate) | 20 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 100's) | RxVAT-exempt | PT Darya-Varia Laboratoria, Tbk.Indonesia | UNILAB, Inc. | DRP-12135 | Jun 20, 2027 | |
AvamaxAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Ranbaxy (Malaysia) SDN. BHDMalaysia | Unilab, Inc.Importer: Ritemed Phils., Inc. | DRP-1234-02 | Feb 2, 2029 | |
AvamaxAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 100's | RxVAT-exempt | Lek Pharmaceuticals D.D.Slovenia | Unilab, Inc.Importer: Sandoz Philippines Corporation | DRP-2272-01 | Jul 3, 2029 | |
AvamaxAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Amherst Laboratories IncPhilippines | Trader: UNILAB, Inc. | DR-XY44385 | Sep 30, 2029 | |
AvamaxAtorvastatin (As Calcium trihydrate) | 40 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 100's) | RxVAT-exempt | PT Darya-Varia Laboratoria, Tbk.Indonesia | UNILAB, Inc. | DRP-12134 | Jun 20, 2027 | |
AvamaxAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 100's | RxVAT-exempt | Ranbaxy (Malaysia) SDN. BHDMalaysia | UNILAB, INC.Importer: Ritemed Phils., Inc. | DRP-1232-02 | Feb 2, 2029 | |
AvamaxAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lek Pharmaceuticals D.D.Slovenia | Unilab Inc.Importer: Sandoz Philippines Corporation | DRP-2279-02 | Aug 13, 2029 | |
AvamaxAtorvastatin (as calcium) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Amherst Laboratories IncPhilippines | Trader: UNILAB, Inc. | DR-XY44384 | Sep 30, 2029 | |
AvamaxAtorvastatin (as calcium trihydrate) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lek S.A.Poland | UNILAB, Inc.Importer: Sandoz Philippines Corporation | DRP-15498-01 | Jul 29, 2029 | |
AvamaxAtorvastatin (as Calcium) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 5's (Box of 30's) | RxVAT-exempt | Lek Pharmaceuticals D.D.Slovenia | Unilab, Inc.Importer: Sandoz Philippines Corporation | DRP-2273-01 | Aug 13, 2029 | |
Avarix 20Atorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Healer’s Lab (Unit II)India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-13973-01 | May 26, 2028 | |
AvasAtorvastatin (as Calcium) | 10mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's | RxVAT-exempt | MICRO LABS LIMITEDIndia | BROWN & BURK PHILIPPINES, INC. | DRP-7057 | Oct 17, 2027 | |
AvasAtorvastatin (as Calcium) | 20mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Micro Labs LimitedIndia | Brown & Burk Philippines, Inc. | DRP-7056 | Oct 2, 2027 | |
AvasAtorvastatin ( as calcium ) | 40 mg Film Coated TabletAlu/Alu Blister Pack x10's (Box of 30's) | RxVAT-exempt | Micro Labs LimitedIndia | Brown & Burk Philippines Inc. | DRP-9583 | Oct 23, 2028 | |
AvatorAtorvastatin (as Calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 50's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Corbridge Group Phils., Inc. | DR-XY38678 | Oct 29, 2031 | |
AvatorAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 50's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Corbridge Group Phils., Inc. | DR-XY38985 | Jan 26, 2030 | |
AvatorAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu-Alu Blister Pack x 8's (Box of 48's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Corbridge Group Phils., Inc. | DR-XY38908 | Dec 29, 2030 | |
AvatorAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | RxVAT-exempt | Agio Pharmaceuticals Ltd.India | Corbridge Group Phils., Inc.Importer: Ambica International Corporation | DRP-4371-02 | Apr 11, 2028 | |
AvatorAtorvastatin (as Calcium Trihydrate) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 100's | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Corbridge Group Phils., Inc.Importer: Ambica International Corporation | DRP-4295-02 | Mar 13, 2028 | |
AvitorAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 30's) | RxVAT-exempt | Bal Pharma LimitedIndia | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-5128-05 | Feb 12, 2029 | |
AzysnaAtorvastatin (As Calcium Trihydrate) | 20 mg Film-Coated TabletAlu-Alu Blister Pack X 10's (Box of 30's) | RxVAT-exempt | Pinnacle Life Science Pvt. Ltd.India | Novocore Pharma Inc.Importer: Despina Pharma Inc. | DRP-15744-02 | Sep 11, 2029 | |
AZYSNAAtorvastatin (As Calcium Trihydrate) | 40 MG FILM-COATED TABLETAlu-Alu Blister Pack X 10's (Box of 30's) | RxVAT-exempt | Pinnacle Life Science Private LimitedIndia | Novocore Pharma Inc.Importer: Despina Pharma Inc. | DRP-15743-02 | Sep 11, 2029 | |
BellustatAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's) | RxVAT-exempt | Akriti Pharmaceuticals Pvt. Ltd.India | Medhart Pharma Inc.Importer: Aglobal Care, Inc.Trader: PPJ Pharma Pvt. Ltd. | DRP-8059-01 | Mar 27, 2027 | |
BestatinAtorvastatin | 20 mg Film-Coated TabletAlu-Alu Blister Pack x 10’s Box of 50’s and 100’s | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | Littman Drug CorporationImporter: Suhitas Pharmaceuticals Inc. | DRP-1720 | Aug 25, 2029 | |
BestatinAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 50’s); Alu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | Littman Drug CorporationImporter: Suhitas Pharmaceuticals Inc. | DRP-2254 | Feb 9, 2031 | |
BrelvastinAtorvastatin (as Calcium) | 20 mg Film-Coated TabletPVC/Alu Blister x 10's (Box of 100's) | RxVAT-exempt | Kausikh Therapeutics (P) Ltd.India | Brel Pharmaceutical Inc. | DRP-4450 | Jun 5, 2031 | |
BrelvastinAtorvastatin (as calcium) | 40 mg Film-Coated TabletPVC/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Kausikh Therapeutics (P) Ltd.India | Brel Pharmaceutical Inc. | DRP-4640 | Aug 29, 2031 | |
CaliptrolAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Strip x 10 Tablets per blister strip = 100 tablets in total per unit carton (Box of 100's) | RxVAT-exempt | Ferozsons Laboratories LimitedPakistan | First Global Trading Corporation | DR-XY43920 | Nov 21, 2029 | |
CaliptrolAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Strip x 10's (Box of 100's) | RxVAT-exempt | Ferozsons Laboratories LimitedPakistan | FIRST GLOBAL TRADING CORPORATION | DR-XY43919 | Nov 21, 2029 | |
CaliptrolAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Strip x 10 Tablets (Box of 100's) | RxVAT-exempt | Ferozsons Laboratories LimitedPakistan | First Global Trading Corporation | DRP-11781 | Nov 21, 2029 | |
CarvastAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Crisdy-Na Drug Corporation | DRP-5155-05 | Sep 2, 2028 | |
CarvastAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's and 100’s) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Crisdy-Na Drug Corporation | DRP-6540-04 | Jul 8, 2029 | |
CholduceAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | D&G PharmaImporter: Ambica International CorporationTrader: Endurance Healthcare Ltd. | DRP-4879-04 | Nov 7, 2028 | |
CholduceAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | D & G PharmaImporter: Ambica International Corporation | DRP-3109-06 | Jul 12, 2029 | |
CholduceAtorvastatin (as Calcium Trihydrate) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | D&G PharmaImporter: Ambica International Corporation | DRP-4295-05 | Mar 13, 2028 | |
CholecurAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 40's (Box of 40's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-5880-03 | Sep 9, 2029 | |
CholecurAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories, Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-6340-03 | Sep 11, 2031 | |
CholecurAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-6339-03 | Sep 22, 2031 | |
CholecurAtorvastatin (as calcium) | 80 mg Film-Coated TabletAlu PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-16342-01 | Feb 12, 2030 | |
CholecurAtorvastatin (as calcium) | 80 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-6341-03 | Oct 30, 2031 | |
Cholemev 20Atorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Healer’s Lab (Unit II)India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-13973-02 | May 26, 2028 | |
Cholemev 40Atorvastatin (as calcium trihydrate) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of l00's) | RxVAT-exempt | Healer’s Lab (Unit II)India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-15961-01 | Oct 4, 2029 | |
Choless 20Atorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's & 100's) | RxVAT-exempt | Healer’s Lab (Unit II)India | Alpha Farmaceutico Corp.Importer: Pharmakon Biotec Inc. | DRP-13973-06 | May 26, 2028 | |
CholtrolAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | RxVAT-exempt | Agio Pharmaceuticals LimitedIndia | Ambica International Corporation | DRP-2796 | Jul 10, 2031 | |
CholtrolAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | RxVAT-exempt | Agio Pharmaceuticals Ltd.India | Ambica International Corporation | DRP-2798 | Jul 13, 2031 | |
CholtrolAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's and 100's) | RxVAT-exempt | Agio Pharmaceuticals Ltd.India | Ambica International Corporation | DRP-4371 | Apr 11, 2028 | |
CorestalAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 7's Box of 28's; Alu/Alu Blister Pack x 10's Box of 30's and 100's | RxVAT-exempt | Dr. Reddy's Laboratories Ltd. (Formulation Unit 3)India | SMHP PHARMACEUTICALS INCORPORATED | DRP-5074 | May 24, 2027 | |
CorestalAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu blister pack x 7's (Box of 28's); Alu/Alu blister pack x 10's (Box of 30's and100's) | RxVAT-exempt | Dr. Reddy's Laboratories Ltd. (Formulation Unit 3)India | SMHP Pharmaceuticals Incorporated | DRP-5075 | May 24, 2027 | |
CorestalAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu-Alu Blister Pack x 7's (Box of 28's); Alu-Alu Blister Pack x 10's (Box of 30's and100's) | RxVAT-exempt | Dr. Reddy's Laboratories Ltd. (Formulation Unit 3)India | SMHP Pharmaceuticals Incorporated | DRP-5047 | May 24, 2027 | |
CrystorvasAtorvastatin (as calcium trihydrate) | 20mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Duopharma Manufacturing (Bangi) Sdn. Bhd.Malaysia | DB (Philippines), Inc. | DR-XY48765 | Jun 6, 2028 | |
CrystorvasAtorvastatin (as calcium trihydrate) | 40mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Duopharma Manufacturing (Bangi) Sdn. Bhd.Malaysia | DB (Philippines), Inc. | DR-XY48766 | Jun 6, 2028 | |
DescolAtorvastatin (as calcium trihydrate) | 10 mg Film-Coated TabletAlu/PVC Blister Pack x 10's Box of 10's | RxVAT-exempt | Nabiqasim Industries (Private) LimitedPakistan | Accesspoint International Trading Inc. | DR-XY44886 | Oct 28, 2028 | |
DescolAtorvastatin (as calcium trihydrate) | 20 mg Film-Coated TabletAlu/PVC Blister pack x 10's Box of 10's | RxVAT-exempt | Nabiqasim Industries (Private) LimitedPakistan | Accesspoint International Trading Inc. | DR-XY44885 | Oct 28, 2028 | |
Duvaztor-20Atorvastatin | 20 mg Film-Coated TabletAlu-Alu Blister Pack x 10’s (Box of 50’s and 100’s) | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | HLM Pharmaceutical Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-1720-03 | Aug 25, 2029 | |
Duvaztor-40Atorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10‘s (Box of 50’s and 100’s) | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | HLM Pharmaceutical Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-2254-03 | Mar 12, 2031 | |
DystatinAtorvastatin (as Calcium) | 10 mg Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | — | DRP-5589 | Jun 27, 2028 | |
DystatinAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Actimed, Inc. | DRP-6540 | Jul 8, 2029 | |
DystatinAtorvastatin (as calcium) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | — | DRP-6818 | Feb 9, 2030 | |
Eldi-ElAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/ PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Medisure Laboratories Pakistan (Pvt.) Ltd.Pakistan | Euro-Care Products PhilippinesImporter: Accesspoint International Trading Inc. | DRP-6126-02 | Apr 5, 2037 | |
EmdistatAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu / ALu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Zest PharmaIndia | MD9 Pharma and Distribution Inc.Importer: Sahar International Trading Inc.Trader: NGB Laboratories Pvt. Ltd., | DRP-16531-01 | Mar 16, 2030 | |
EndvastorAtorvastatin (as Calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-3123-04 | Jul 12, 2029 | |
Eostatin 80Atorvastatin (as calcium) | 80 mg Film-Coated TabletAlu-Alu Blister Pack 1 x 10's (Box of 30's) | RxVAT-exempt | Umedica Laboratories Pvt. LtdIndia | Eon Pharmatek, Inc. | DRP-16247 | Jan 9, 2030 | |
Farmavast 20Atorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | RxVAT-exempt | Agio Pharmaceuticals LimitedIndia | Diafarm Inc.Importer: Ambica International Corporation | DRP-2796-02 | Sep 4, 2037 | |
FaticonAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Healer’s Lab (Unit II)India | Neos-King Pharma Inc.Importer: Pharmakon Biotec Inc. | DRP-13973-03 | May 26, 2028 | |
FedstatinAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Federal Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-10747-02 | Aug 6, 2037 | |
FedstatinAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Federal Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-10748-04 | Aug 17, 2037 | |
FlorvastAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Bansan Pharma DistributorImporter: Ambica International Corporation | DRP-3109-05 | Jul 12, 2029 | |
Florvast 80Atorvastatin (as Calcium Trihydrate) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Bansan Pharma DistributorImporter: Ambica International Corporation | DRP-4295-03 | Mar 13, 2028 | |
FredtorAtorvastatin (As Calcium) | 10mg Film Coated TabletsAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-11881 | May 18, 2027 | |
FredtorAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises, Inc. | DRP-11880 | May 18, 2032 | |
FredtorAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals Ltd.India | AMB HK Enterprises Inc. | DRP-11879 | May 18, 2032 | |
FredtorAtorvastatin (As Calcium) | 80mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-11878 | May 18, 2027 | |
FtorAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-15841 | Sep 20, 2029 | |
FtorAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-15842 | Sep 20, 2029 | |
FtorAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-15843 | Sep 20, 2029 | |
FtorAtorvastatin (as calcium) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-15844 | Sep 20, 2029 | |
FulvastAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAluminum Strip Foil x 10's (Box of 100's) | RxVAT-exempt | Diamond Laboratories Inc.Philippines | Full Health International Pharma | DRP-7606 | Jun 17, 2029 | |
FulvastAtorvastatin (as Calcium) | 80 mg Film-Coated TabletAluminum Strip Foil x 10's (Box of 100's) | RxVAT-exempt | Diamond Laboratories, Inc.Philippines | Full Health International Pharma | DRP-7605 | May 23, 2029 | |
Genvazt-20Atorvastatin (as Calcium Trihydrate) | 20mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | ACME Formulations Pvt. Ltd.India | GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical, Inc. | DRP-12155-01 | Jun 22, 2027 | |
Gitor-40Atorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Gijun Trading Inc.Importer: Ambica International Corporation | DRP-3109-10 | Jul 12, 2029 | |
Globastat-20Atorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's and 100's) | RxVAT-exempt | Akriti Pharmaceuticals Pvt. Ltd.India | Qualifirst Health, Inc.Importer: Aglobal Care, Inc.Trader: PPJ Pharma Pvt. Ltd. | DRP-8059 | Mar 27, 2027 | |
Gostat 10Atorvastatin | 10 mg Film-Coated TabletAlu-Alu Blister Pack x 10’s Box of 100’s | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | Applied Pharmaceuticals Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-1721-03 | Aug 25, 2029 | |
Gostat 20Atorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-9837-01 | Jun 23, 2031 | |
Gostat-40Atorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10‘s (Box of 100’s) | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-2254-04 | Mar 12, 2031 | |
Gostin-10Atorvastatin (as Calcium Trihydrate) | 10 mg Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 30's. Box of 100's) | RxVAT-exempt | ACME Formulations Pvt. Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Medinova Pharmaceutical Inc. | DRP-12225-02 | Jul 12, 2027 | |
Gostin-10Atorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's and 30's) | RxVAT-exempt | Ratnaris Pharmaceuticals Private LimitedIndia | Applied Pharmaceutical Distribution Inc.Importer: Medinova Pharmaceutical Inc. | DRP-15715-02 | Sep 5, 2029 | |
Gostin-20Atorvastatin (as Calcium Trihydrate) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, Box of 100's) | RxVAT-exempt | Acme Formulations Pvt. Ltd.India | Applied Pharmaceutical DistributionImporter: Medinova Pharmaceutical Inc. | DRP-12155-03 | Jun 22, 2027 | |
Gostin-20Atorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's; Box of 100's) | RxVAT-exempt | Ratnatris Pharmaceuticals Private LimitedIndia | Applied Pharmaceutical Distribution Inc.Importer: Medinova Pharmaceutical Inc. | DRP-15714-01 | Sep 6, 2029 | |
Gotorvast 10Atorvastatin (As Calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Applied Pharmaceutical Distribution Inc.Importer: AMB HK Enterprises Inc. | DRP-14015-01 | Jun 6, 2028 | |
Gotorvast 20Atorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Applied Pharmaceutical Distribution Inc.Importer: AMB HK Enterprises Inc. | DRP-14014-01 | Jun 6, 2028 | |
Gotorvast 40Atorvastatin (As Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Applied Pharmaceutical Distribution Inc.Importer: AMB HK Enterprises Inc. | DRP-14013-01 | Jun 6, 2028 | |
Gotorvast 80Atorvastatin (as Calcium) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s and 100’s) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Applied Pharmaceutical Distribution Inc.Importer: AMB HK Enterprises Inc. | DRP-14012-02 | Jun 6, 2028 | |
GovastinAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Ambica International Corporation | DRP-3109-08 | Jul 12, 2029 | |
GovastinAtorvastatin (as calcium) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Applied Pharmaceutical Distribution IncImporter: Ambica International Corporation | DRP-10749-07 | Nov 15, 2031 | |
H-Ator 20Atorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 50’s and 100's) | RxVAT-exempt | Bioveeta Laboratories Pvt. Ltd.India | Intermac Pharmaceutical Inc. | DRP-5815 | Sep 3, 2029 | |
ItorvazAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | The ACME Laboratories Ltd.Bangladesh | Bell-Kenz Pharma Inc.Importer: Euro Generics International Phils., Inc. | DRP-3654 | Aug 3, 2031 | |
ItorvazAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 30's) | RxVAT-exempt | The ACME Laboratories LimitedBangladesh | Bell-Kenz Pharma Inc.Importer: Euro Generics International Phils., Inc. | DRP-6081 | May 18, 2027 | |
ItorvazAtorvastatin (as Calcium) | 80 mg Film-coated TabletAlu/Alu Blister Pack of 10's (Box of 30's) | RxVAT-exempt | The ACME Laboratories LimitedBangladesh | Bell-Kenz Pharma Inc.Importer: Euro Generics International Phils., Inc. | DRP-6080 | May 18, 2027 | |
Khrizstatin 40Atorvastatin (as calcium) | 40 mg Film-Coated TabletAlu-Alu blister x 10's (Box of 100's) | RxVAT-exempt | Ceclogen Generics Private Ltd.India | Importer: Khriz Pharma Trading Inc. | DRP-13270 | Feb 8, 2028 | |
Klotor-SAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Starpharm, Inc.Importer: Ambica International Corporation | DRP-3109-09 | Jul 12, 2029 | |
KoditorzAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Kodi Biosciences IncImporter: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-5137-06 | Feb 13, 2029 | |
KorvastAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Opaque White PVC blister pack x 40's Box of 40's | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Konzept Convenience and Drug Store Corp. | DRP-5880-04 | Sep 9, 2029 | |
KorvastAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | KONZEPT CONVENIENCE AND DRUG STORE CORP. | DRP-6340-04 | Sep 25, 2031 | |
KorvastAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Konzept Convenience And Drug Store Corp. | DRP-6339-04 | Sep 19, 2031 | |
KorvastAtorvastatin (as Calcium) | 80 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Konzept Convenience And Drug Store Corp. | DRP-6341-04 | Sep 19, 2031 | |
Lemchole 20Atorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation | DRP-10747-09 | Aug 6, 2037 | |
Lemtor 10Atorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Rilem Pharma Corp.Importer: Ambica International Corporation | DRP-10746-04 | Sep 22, 2031 | |
Lemtor 20Atorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Rilem Pharma Corp.Importer: Ambica International Corporation | DRP-10747-10 | Oct 17, 2031 | |
Lemtor 40Atorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Rilem Pharma Corp.Importer: Ambica International Corporation | DRP-10748-08 | Sep 23, 2031 | |
Lemtor 80Atorvastatin (as calcium) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Rilem Pharma Corp.Importer: Ambica International Corporation | DRP-10749-04 | Sep 4, 2031 | |
LestorAtorvastatin (As Calcium) | 10mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-14015 | Jun 6, 2028 | |
LestorAtorvastatin (As Calcium) | 20mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-14014 | Jun 6, 2028 | |
LestorAtorvastatin (As Calcium) | 40mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-14013 | Jun 6, 2028 | |
LestorAtorvastatin (As Calcium) | 80mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-14012 | Jun 6, 2028 | |
LieutenantAtorvastatin (as calcium) | 40 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-6922-01 | Oct 10, 2031 | |
Lifetor 10Atorvastatin (as Calcium Trihydrate) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's; Box of 100's) | RxVAT-exempt | ACME Formulations Pvt. Ltd.India | Life And Health Source Pharmaceutical Distribution Co.Importer: Medinova Pharmaceutical Inc. | DRP-12225-04 | Jul 12, 2027 | |
Lifetor 20Atorvastatin (as Calcium Trihydrate) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's; Box of 100's) | RxVAT-exempt | ACME Formulations Pvt. Ltd.India | Life and Health Source Pharmaceutical Distribution Co.Importer: Medinova Pharmaceutical, Inc. | DRP-12155-04 | Jun 22, 2027 | |
LifortAtorvastatin (as Calcium) | 10 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 30's) | RxVAT-exempt | Bal Pharma LimitedIndia | Pharmakon Biotec Inc. | DRP-5127 | Feb 12, 2029 | |
LifortAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 30's) | RxVAT-exempt | Bal Pharma LimitedIndia | Pharmakon Biotec Inc. | DRP-5128 | Feb 12, 2029 | |
Linmervast-20Atorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-4879-05 | Nov 7, 2028 | |
Linmervast-40Atorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Linmer Pharma IncorporatedImporter: Ambica International CorporationTrader: Endurance Healthcare Ltd. | DRP-5137-02 | Feb 13, 2029 | |
Lipend 10Atorvastatin (as Calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International CorporationTrader: Endurance Healthcare Ltd. | DRP-5339 | Jun 18, 2029 | |
Lipend 20Atorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Macropharma CorporationImporter: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-4879 | Nov 7, 2028 | |
LipiblacAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | RSG Pharma TradingImporter: Ambica International CorporationTrader: Endurance Healthcare Ltd. | DRP-4879-03 | Nov 7, 2028 | |
Lipimize-A 15Atorvastatin (as besilate) + Atorvastatin (as calcium) | 5 mg/10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-6802 | Aug 19, 2030 | |
LipinilAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 50's) | RxVAT-exempt | Bioveeta Laboratories Pvt. LtdIndia | Jaera Pharma And Medical Supplies TradingImporter: Intermac Pharmaceutical Inc. | DRP-5815-02 | Sep 3, 2029 | |
Lipinov 10Atorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Ratnatris Pharmaceuticals Private LimitedIndia | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-15715-03 | Sep 5, 2029 | |
Lipinov 20Atorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Ratnatris Pharmaceuticals Private LimitedIndia | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-15714-03 | Sep 6, 2029 | |
LipitorAtorvastatin (as calcium) | 10 mg TabletAlu-PA/Alu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Pfizer Pharmaceuticals LLCPuerto Rico | Importer: PF OFG Philippines Inc. | DRP-3361 | Jun 29, 2027 | |
LipitorAtorvastatin (as calcium) | 20 mg TabletAlu-PA/Alu/PVC Blister Pack (Box of 10 blister packs x 10's) | RxVAT-exempt | Pfizer Pharmaceuticals LLCPuerto Rico | Importer: PF OFG Philippines Inc. | DRP-3362 | Jul 21, 2027 | |
LipitorAtorvastatin (as calcium) | 40 mg TabletAlu-PA/Alu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Pfizer Pharmaceuticals LLCPuerto Rico | Importer: PF OFG Philippines Inc. | DRP-3363 | Jun 29, 2027 | |
LipitorAtorvastatin (as calcium) | 80 mg TabletAlu-PA/Alu/PVC Blister Pack x 10's (Box of 10's); Alu-PA/Alu/PVC Blister Pack x 1's (Box of 1's) as Physician's Sample | RxVAT-exempt | Pfizer Pharmaceuticals LLCPuerto Rico | Importer: PF OFG Philippines Inc. | DRP-3364 | Jul 21, 2027 | |
LipitrolAtorvastatin | 10 mg TabletWhite opaque PVC/Alu foil blister pack x 10's (Box of 100's) | RxVAT-exempt | Scheele Laboratories Phils., IncPhilippines | — | DRP-7531 | Dec 1, 2027 | |
LipitrolAtorvastatin | 20 mg TabletClear PVC/Alu foil blister pack x 10's (Box of 100's) | RxVAT-exempt | Scheele Laboratories Phils., Inc.Philippines | — | DRP-7530 | Dec 1, 2027 | |
LipitrolAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Scheele Laboratories Phil. Inc.Philippines | — | DRP-8593 | Dec 20, 2029 | |
Lipizen-20Atorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Kodapharm Med Corp.Importer: Ambica International Corporation | DRP-10747-05 | Sep 19, 2037 | |
Lipizen-40Atorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Kodapharm Med Corp.Importer: Ambica International Corporation | DRP-10748-06 | Aug 12, 2037 | |
Lipotrim-40Atorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's and 100's) | RxVAT-exempt | Maple Pharmaceuticals (Pvt.) Ltd.Pakistan | Ambica International Corporation | DRP-4697 | Sep 13, 2028 | |
LolipAtorvastatin (as Calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 50's) | RxVAT-exempt | Kusum Healthcare Private LimitedIndia | Kusum Healthcare Private Limited Branch Office | DR-XY42472 | Mar 4, 2031 | |
LolipAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's and 50's) | RxVAT-exempt | Kusum Healthcare Pvt. Ltd.India | Kusum Healthcare Private Limited Branch Office | DRP-10505 | Mar 6, 2031 | |
Madrovas-20Atorvastatin (as calcium trihydrate) | 20 mg Film-Coated TabletAlu/Alu blister pack x 10 tablets (Box of 30 tablets) | RxVAT-exempt | The Madras PharamceuticalsIndia | Aglobal Care, Inc. | DRP-13501 | Mar 2, 2028 | |
Mayor 10Atorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-10746-02 | Aug 17, 2037 | |
Mayor 20Atorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-10747-07 | Aug 17, 2037 | |
Mayor 80Atorvastatin (as calcium) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-10749-02 | Aug 12, 2037 | |
Mayor-40Atorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-10748-01 | Aug 6, 2037 | |
Medivazt-20Atorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Ratnatris Pharmaceuticals Private LimitedIndia | Medinova Pharmaceutical Inc. | DRP-15714 | Sep 6, 2029 | |
MEVAGARDAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 8's Box of 40's | RxVAT-exempt | J.M. TOLMANN LABORATORIES INC.Philippines | WESTFIELD PHARMACEUTICALS, INC. | DRP-3175-02 | Jan 4, 2030 | |
NeostatAtorvastatin (as calcium) | 10 mg TabletWhite Opaque PVC/Alu Foil Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Scheele Laboratories Phils., Inc.Philippines | PHARMA HUB CORPORATION | DRP-7531--01 | Dec 1, 2027 | |
NeostatAtorvastatin (as calcium) | 20 mg TabletClear PVC/Alu Foil Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Scheele Laboratories Phils., Inc.Philippines | Pharma Hub Corporation | DRP-7530-01 | Dec 1, 2027 | |
NeostatinAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-10746-03 | Aug 6, 2037 | |
NeostatinAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-10747-08 | Aug 17, 2037 | |
NeostatinAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-10748-07 | Aug 6, 2037 | |
NeostatinAtorvastatin (as calcium) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-10749-01 | Aug 19, 2037 | |
NoneAtorvastatin (as Calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30s) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Dyna Drug Corporation | DR-XY38612 | Oct 11, 2030 | |
NoneAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Ultramed Pharma, Inc. | DR-XY44229 | Feb 27, 2030 | |
NoneAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-10746-05 | Nov 15, 2031 | |
NoneAtorvastatin (as Calcium Trihydrate) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Acme Formulations Pvt. Ltd.India | Qualifirst Health Inc.Importer: Medinova Pharmaceutical, Inc. | DRP-12225-05 | Jul 12, 2027 | |
NoneAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu / Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Medisky PharmaceuticalsIndia | SwissPharmatech Co.Importer: Aglobal Care, Inc. | DRP-15640-01 | Aug 14, 2029 | |
NoneAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | RxVAT-exempt | Agio Pharmaceuticals LimitedIndia | International Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-2796-01 | Sep 22, 2037 | |
NoneAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100’s) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Rose Pharmacy, Incorporated | DRP-5589-03 | Jun 27, 2028 | |
NoneAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | St. Joseph DrugstoreTrader: Innogen Pharmaceuticals, Inc. | DRP-5614-05 | Mar 19, 2029 | |
NoneAtorvastatin (as calcium) | 10 mg TabletAlu-PA/Alu/PVC Blister Pack 10's Box of 100's | RxVAT-exempt | Pfizer Pharmaceuticals LLCPuerto Rico | PHILUSA CORPORATIONImporter: PF OFG Philippines, Inc. | DRP-3361-02 | Jun 29, 2027 | |
NoneAtorvastatin | 10 mg TabletAlu-PA / Alu/ PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Viatris Pharmaceuticals LLCUSA | Viatris Pharmaceuticals, Inc.Importer: Viatris, Inc. | DRP-3361-03 | Jun 29, 2027 | |
NoneAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Dyna Drug Corporation | DR-XY39434 | May 10, 2031 | |
NoneAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Alkem Laboratories CorporationImporter: Ambica International Corporation | DRP-10747-01 | Sep 11, 2037 | |
NoneAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | PharmaVital Corp.Importer: Ambica International Corporation | DRP-10747-11 | Nov 15, 2031 | |
NoneAtorvastatin (as Calcium Trihydrate) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Acme Formulation Pvt. Ltd.India | Qualifirst Health Inc.Importer: Medinova Pharmaceutical Inc. | DRP-12155-05 | Jun 22, 2027 | |
NoneAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu-Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DRP-2383 | May 21, 2029 | |
NoneAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu-Alu Blister Pack x 10’s (Box of 30’s and Box of 50’s) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Pharex Healthcare CorporationImporter: Ambica International Trading Corp. | DRP-2922 | Apr 14, 2031 | |
NoneAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-4879-01 | Nov 7, 2028 | |
NoneAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Corbridge Group Phils., Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Ltd. | DRP-4879-02 | Nov 7, 2028 | |
NoneAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | International Pharmaceuticals, Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Ltd. | DRP-4879-06 | Nov 7, 2028 | |
NoneAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Rose Pharmacy, Incorporated | DRP-5155-04 | Sep 2, 2028 | |
NoneAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Medisure Laboratories Pakistan (Pvt.) LimitedPakistan | Reta DrugImporter: Accesspoint International Trading Inc. | DRP-6126-03 | Mar 21, 2037 | |
NoneAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu-PVC Blister White Opaque x 10’s (Box of 100’s) | RxVAT-exempt | Sydenham Laboratories, Inc.Philippines | Actimed, Inc. | DRP-6128-04 | May 5, 2031 | |
NoneAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | St. Joseph DrugstoreTrader: Innogen Pharmaceuticals, Inc. | DRP-7120-01 | Mar 19, 2029 | |
NoneAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's and 100's) | RxVAT-exempt | Akriti Pharmaceuticals Pvt. LtdIndia | TGP Pharma Inc.Importer: Aglobal Care, IncTrader: PPJ Pharma Pvt. Ltd | DRP-8059-02 | Mar 27, 2027 | |
NoneAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100's) | RxVAT-exempt | Akriti Pharmaceuticals Pvt. LtdIndia | SwissPharmatech Co.Importer: Aglobal Care, Inc.Trader: PPJ Pharma Pvt. Ltd | DRP-8059-04 | Mar 27, 2027 | |
NoneAtorvastatin (as calcium) | 20 mg TabletAlu-PA/Alu/PVC Blister Pack (Box of 100's) | RxVAT-exempt | Pfizer Pharmaceutical LLCPuerto Rico | PHILUSA CORPORATIONImporter: PF OFG Philippines, Inc. | DRP-3362-02 | Jul 21, 2027 | |
NoneAtorvastatin | 20 mg TabletAlu-PA/Alu/PVC Blister Pack (Box of 10 blister packs x 10's); (Box of 1 blister pack x 1's as Physician's Sample) | RxVAT-exempt | Viatris Pharmaceuticals LLCUSA | Viatris Pharmaceuticals, Inc.Importer: Viatris, Inc. | DRP-3362-03 | Jul 21, 2027 | |
NoneAtorvastatin (as Calcium) | 20mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Micro Labs LimitedIndia | ADP Pharma CorporationImporter: Brown & Burk Philippines, Inc. | DRP-7056-01 | Oct 2, 2027 | |
NoneAtorvastatin (as calcium) | 40 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Micro Labs LimitedIndia | ADP Pharma CorporationImporter: Brown & Burk Philippines Inc. | DRP-9583-01 | Oct 23, 2028 | |
NoneAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Alkem Laboratories CorporationImporter: Ambica International Corporation | DRP-10748-02 | Aug 17, 2037 | |
NONEAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | PharmaVital Corp.Importer: Ambica International Corporation | DRP-10748-09 | Nov 15, 2031 | |
NoneAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | Dyna Drug CorporationImporter: AMB HK Enterprises Inc. | DRP-11879-01 | May 18, 2027 | |
NoneAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Ranbaxy (Malaysia) SDN. BHDMalaysia | Ritemed Phils., Inc. | DRP-1232 | Feb 2, 2029 | |
NoneAtorvastatin (As Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30’s and 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Qualifirst Health Inc.Importer: AMB HK Enterprises Inc. | DRP-14013-04 | Jun 6, 2028 | |
NoneAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lek Pharmaceuticals D.D.Slovenia | Watsons Personal Care Stores (Philippines), Inc.Importer: Sandoz Philippines Corporation | DRP-2279-01 | Aug 13, 2029 | |
NoneATORVASTATIN (AS CALCIUM) | 40 MG FILM-COATED TABLETALU/ALU BLISTER PACK X 8'S BOX OF 40'S | RxVAT-exempt | J.M. TOLMANN LABORATORIES INC.Philippines | TGP Pharma, Inc. | DRP-3175 | Jan 4, 2030 | |
NoneAtorvastatin (as Calcium) | 40 MG FILM-COATED TABLETALU/ALU BLISTER PACK X 8 'S BOX OF 40'S | RxVAT-exempt | J.M. TOLMANN LABORATORIES INC.Philippines | FIRSTMED THERACONCEPT INC. | DRP-3175-07 | Jan 4, 2030 | |
NoneAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | United Laboratories, Inc.Importer: Ambica International Corporation | DRP-3224 | Sep 2, 2029 | |
NoneAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Actimed, Inc.Importer: Ambica International Corporation | DRP-3224-01 | Sep 2, 2029 | |
NoneAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | RxVAT-exempt | Agio Pharmaceuticals Ltd.India | South Star DrugImporter: Ambica International Corporation | DRP-4371-01 | Apr 11, 2028 | |
NoneAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: Endurance Healthcare Ltd. | DRP-5137-01 | Feb 13, 2029 | |
NoneAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Ltd. | DRP-5137-03 | Feb 13, 2029 | |
NoneAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | International Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-5137-04 | Feb 13, 2029 | |
NoneAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s and Box of 100’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Actimed, Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-5137-07 | Feb 13, 2029 | |
NoneAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu-PVC Blister White Opaque x 10’s (Box of 100’s) | RxVAT-exempt | Sydenham Laboratories, Inc.Philippines | Actimed, Inc. | DRP-6125-01 | May 5, 2031 | |
NoneAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Rose Pharmacy, Incorporated | DRP-6540-03 | Jul 8, 2029 | |
NoneAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 24's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | St. Joseph DrugstoreTrader: Dr. Zen’s Research, Inc. | DRP-7551-02 | May 12, 2030 | |
NoneAtorvastatin (as calcium) | 40 mg TabletAlu-PA/Alu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Pfizer Pharmaceuticals LLCPuerto Rico | Philusa CorporationImporter: PF OFG Philippines, Inc. | DRP-3363-02 | Jun 29, 2027 | |
NoneAtorvastatin | 40 mg TabletAlu-PA/Alu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Viatris Pharmaceuticals LLCUSA | Viatris Pharmaceuticals, Inc.Importer: Viatris, Inc. | DRP-3363-03 | Jun 29, 2027 | |
NoneAtorvastatin (as calcium) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 24's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Euro-Health Care Exponents, Inc. | DR-XY37435 | Feb 4, 2030 | |
NoneAtorvastatin (as calcium) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Reta DrugImporter: Ambica International Corporation | DRP-10749-03 | Aug 17, 2037 | |
NoneAtorvastatin (As Calcium) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30’s and 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Qualifirst Health Inc.Importer: AMB HK Enterprises Inc. | DRP-14012-03 | Jun 6, 2028 | |
NoneAtorvastatin (as calcium trihydrate) | 80 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 100’s) | RxVAT-exempt | Healer's Lab (Unit II)India | Reta DrugImporter: Pharmakon Biotec Inc. | DRP-15406-02 | Jul 3, 2029 | |
NoneAtorvastatin (as Calcium Trihydrate) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Alkem Laboratories CorporationImporter: Ambica International Corporation | DRP-4295-04 | Mar 13, 2028 | |
NoneAtorvastatin (as calcium) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | TGP Pharma Inc. | DRP-6818-01 | Feb 9, 2030 | |
NoneAtorvastatin (as calcium) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Rose Pharmacy, Incorporated | DRP-6818-02 | Feb 9, 2030 | |
NoneAtorvastatin (as calcium) | 80 mg TabletAlu-PA/Alu/PVC Blister Pack x 10's Box of 100's | RxVAT-exempt | Pfizer Pharmaceuticals LLCPuerto Rico | PHILUSA CORPORATIONImporter: PF OFG Philippines, Inc. | DRP-3364-02 | Jul 21, 2027 | |
NoneAtorvastatin | 80 mg TabletAlu-PA /Alu/ PVC Blister Pack x 10's (Box of 100's); Alu-PA/Alu/PVC Blister Pack x 1's (Box of 1's) as Physician's Sample | RxVAT-exempt | Viatris Pharmaceuticals LLCUSA | Viatris Pharmaceuticals, Inc.Importer: Viatris, Inc. | DRP-3364-03 | Jul 21, 2027 | |
Novaztor 20Atorvastatin Calcium | 20mg Film-Coated TabletAlu-Alu Blister Pack by 10’s (Box of 30's and 100’s) | RxVAT-exempt | Salud Care (India) LimitedIndia | Medinova Pharmaceutical Inc. | DRP-19157 | Nov 11, 2031 | |
Novaztor-40Atorvastatin Calcium | 40mg Film-Coated TabletAlu-Alu Blister x 10’s (Box of 30’s and 100’s) | RxVAT-exempt | Salud Care (India) LimitedIndia | Medinova Pharmaceutical Inc. | DRP-19156 | Nov 11, 2031 | |
NutorAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 50's and 100's) | RxVAT-exempt | Bioveeta Laboratories Pvt. Ltd.India | Kodapharm Med Corp.Importer: Intermac Pharmaceutical Inc. | DRP-5815-01 | Sep 3, 2029 | |
OnestatinAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | — | DR-XY42164 | Jun 27, 2028 | |
OnestatinAtorvastatin (as calcium) | 20 mg Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | One Pharma Marketing Inc. | DRP-4633 | Dec 26, 2027 | |
OP-AtorAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | Orient Pearl Med Pharma, Inc.Importer: AMB HK Enterprises Inc. | DRP-11880-01 | May 18, 2027 | |
OP-ATORAtorvastatin (as Calcium Trihydrate) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Healer's Lab (Unit II)India | Orient Pearl Med Pharma Inc.Importer: Pharmakon Biotec Inc. | DRP-15961-05 | Oct 4, 2029 | |
OrvastAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 40's) | RxVAT-exempt | J.M. TOLMANN LABORATORIES INC.Philippines | Medirich Pharma Distribution Corp. | DRP-3175-01 | Jan 4, 2030 | |
ProtemaxAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Ranbaxy (M) Sdn. Bhd.Malaysia | UNILAB, INC. | DRP-1233-01 | Feb 2, 2029 | |
ProtemaxAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Ranbaxy (Malaysia) Sdn. Bhd.Malaysia | Unilab Inc. | DRP-1234-01 | Feb 2, 2029 | |
ProtemaxAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 100's | RxVAT-exempt | Ranbaxy (Malaysia) SDN. BHDMalaysia | UNILAB, INC. | DRP-1232-01 | Aug 12, 2037 | |
ProvasAtorvastatin (as calcium) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 24's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Dr. Zen’s Research, Inc. | DR-XY37441 | Feb 9, 2030 | |
Q-TorAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Quad-Gen PharmaceuticalsImporter: Ambica International Corporation | DRP-3109-07 | Jul 12, 2029 | |
RanvastAtorvastatin(As Calcium) | 20 mg Film-Coated TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | Philgen Pharmaceuticals, Inc. | DRP-2778 | Jul 14, 2027 | |
RanvastAtorvastatin (as calcium) | 40 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mercury Laboratories Ltd.India | Philgen Pharmaceuticals, Inc. | DRP-16465 | Mar 20, 2030 | |
RanvastAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Centaurion Laboratories Pvt. Ltd.india | Philgen Pharmaceuticals Inc. | DRP-5224 | Jun 28, 2027 | |
RedulipAtorvastatin | 10 mg Film-Coated TabletAlu-Alu Blister Pack x 10’s (Box of 50’s and 100’s) | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | Suhitas Pharmaceuticals Inc. | DRP-1721 | Aug 25, 2029 | |
Regi2RAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 20's (Box of 100's); Alu/Opaque White PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Regimed Pharmaceutical Distributor | DRP-5880-08 | Sep 9, 2029 | |
REGI2RAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 20's (Box of 100's and 200's); Alu/Opaque White PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Regimed Pharmaceutical Distributor | DRP-6340-07 | Sep 11, 2030 | |
REGI2RAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's and 200's); Alu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories, Inc.Philippines | Regimed Pharmaceutical Distributor | DRP-6339-08 | Sep 11, 2030 | |
Regi2RAtorvastatin (as Calcium) | 80 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's); Alu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Regimed Pharmaceutical Distributor | DRP-6341-07 | Sep 11, 2030 | |
RestatAtorvastatin (as Calcium) | 10 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Medisure Laboratories Pakistan (Pvt.) LimitedPakistan | Rexmed Pharmaceutical SalesImporter: Accesspoint International Trading Inc. | DRP-6127-01 | May 20, 2031 | |
RestatAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Medisure Laboratories Pakistan (Pvt.) LimitedPakistan | Rexmed Pharmaceutical SalesImporter: Accesspoint International Trading Inc. | DRP-6126-01 | Apr 16, 2037 | |
RetastatAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | Reta DrugImporter: Suhitas Pharmaceuticals, Inc. | DRP-9838-01 | Jun 23, 2031 | |
RetastatAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Umedica Laboratories Pvt.Ltd.India | Reta DrugImporter: SUHITAS PHARMACEUTICALS INC. | DRP-9837-03 | Jun 23, 2031 | |
RetastatAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10‘s (Box of 100’s) | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | Reta DrugImporter: Suhitas Pharmaceuticals Inc. | DRP-2254-06 | Mar 16, 2031 | |
RetavastatinAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Reta DrugImporter: Ambica International Corporation | DRP-10748-03 | Aug 12, 2037 | |
Saatin 10Atorvastatin (as Calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | GX International, Inc. | DRP-5589-01 | Jun 27, 2028 | |
Saatin 20Atorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | GX International, Inc. | DRP-5155-01 | Sep 2, 2028 | |
Saatin 40Atorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | HIZON LABORATORIES, INC.Philippines | GX INTERNATIONAL, INC. | DRP-6540-01 | Jul 8, 2029 | |
SavtatinAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's & 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-10746-01 | Sep 11, 2037 | |
SavtatinAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-10747-04 | Aug 17, 2037 | |
SavtatinAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-10748-05 | Aug 19, 2037 | |
SavtatinAtorvastatin (as calcium) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-10749-05 | Sep 22, 2031 | |
SITIvast-40Atorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Zest PharmaIndia | Sahar International Trading, Inc. | DR-XY44319 | Mar 16, 2030 | |
SITIvast-40Atorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu blister Pack x 10's (Box of 100's) | RxVAT-exempt | Zest PharmaIndia | Sahar International Trading, Inc.Trader: NGB Laboratories Pvt. Ltd., | DRP-16531 | Mar 16, 2030 | |
StadinAtorvastatin (as calcium trihydrate) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lek S.A.Poland | Stada Philippines, Inc.Importer: Sandoz Philippines Corporation | DRP-15501-01 | Jul 29, 2029 | |
StadinAtorvastatin (as calcium trihydrate) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lek S.A.Poland | Stada Philippines, Inc.Importer: Sandoz Philippines Corporation | DRP-15500-01 | Jul 29, 2029 | |
StadinAtorvastatin (as calcium trihydrate) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lek S.A.Poland | Stada Philippines, Inc.Importer: Sandoz Philippines Corporation | DRP-15499-01 | Jul 29, 2029 | |
Stalip-10Atorvastatin (as Calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-3123 | Jul 12, 2029 | |
Stalip-40Atorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's and 100's | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-3109 | Jul 12, 2029 | |
Stalip-80Atorvastatin (as Calcium Trihydrate) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 100's | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-4295 | Mar 13, 2028 | |
Sunvas 10Atorvastatin (as calcium trihydrate) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sun Pharmaceutical Industries LimitedIndia | Sun Pharma Philippines, Inc. | DRP-15526 | Jul 31, 2029 | |
Sunvas 20Atorvastatin (as calcium trihydrate) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sun Pharmaceutical Industries LimitedIndia | Sun Pharma Philippines, Inc. | DRP-15525 | Jul 31, 2029 | |
Sunvas 40Atorvastatin (as calcium trihydrate) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sun Pharmaceutical Industries LimitedIndia | Sun Pharmaceutical Industries Limited | DRP-15524 | Jul 31, 2029 | |
Sunvas 80Atorvastatin (as calcium trihydrate) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sun Pharmaceutical Industries LimitedIndia | Sun Pharma Philippines, Inc. | DRP-15523 | Jul 31, 2029 | |
SydenvastAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu-PVC Blister White Opaque x 10's (Box of 100's) | RxVAT-exempt | Sydenham Laboratories, Inc.Philippines | — | DRP-6128 | May 5, 2031 | |
SydenvastAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu-PVC Blister White Opaque x 10's (Box of 100's) | RxVAT-exempt | Sydenham Laboratories, Inc.Philippines | — | DRP-6125 | May 5, 2031 | |
TechnostatAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | One Technodrug Life Sciences Inc.Importer: Ambica International Corporation | DRP-3109-01 | Jul 12, 2029 | |
Technostat-10Atorvastatin (as Calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | One Technodrug Life Sciences Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Ltd. | DRP-5339-02 | Jun 18, 2029 | |
TenienteAtorvastatin (as calcium) | 40 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-6922-02 | Oct 16, 2031 | |
TG-TorAtorvastatin | 20 mg Film-Coated TabletsClear PVC / Alu foil blister pack x 10's (Box of 100's) | RxVAT-exempt | Scheele Laboratories Phils., Inc.Philippines | TGIF Pharmaceutical Trading Inc. | DRP-7530-04 | Dec 1, 2027 | |
Thor-40Atorvastatin (as calcium trihydrate) | 40 mg Film-Coated TabletAlu/ Alu Blister Pack x 10's (Box of 100’s) | RxVAT-exempt | Healer's Lab (Unit II)India | RL Pharma Enterprises Inc.Importer: Pharmakon Biotec Inc. | DRP-15961-02 | Oct 4, 2029 | |
ToravasAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Akriti Pharmaceuticals Pvt. Ltd.India | The Cathay YSS Distributors Co., Inc.Importer: Aglobal Care, Inc. | DRP-8059-03 | Mar 27, 2027 | |
ToravasAtorvastatin (As Calcium) | 40 mg Film-Coated TabletAlu / Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | The Cathay YSS Distributors Co., IncImporter: AMB HK Enterprises Inc. | DRP-14013-03 | Jun 6, 2028 | |
ToravasAtorvastatin (As Calcium) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | The Cathay YSS Distributors Co., IncImporter: AMB HK Enterprises Inc. | DRP-14012-01 | Jun 6, 2028 | |
Tored-10Atorvastatin (as Calcium) | 10 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 20's) | RxVAT-exempt | SAPPHIRE LIFESCIENCES PVT. LTDIndia | 777 Red Pharma Inc.Importer: NELPA LIFESCIENCES, INC. | DRP-4470-01 | Jun 13, 2028 | |
Tored-20Atorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 20's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | 777 Red Pharma Inc.Importer: Nelpa Lifesciences, Inc. | DRP-5211-01 | Mar 5, 2029 | |
TORED-20Atorvastatin (as Calcium) | Film-Coated Tablet 20 mgAlu-Alu Blister Pack x 10’s (Box of 20’s, 30's, 60's, 90's & 100's) | RxVAT-exempt | Genom Biotech Pvt. Ltd.India | 777 Red Pharma Inc.Importer: Nelpa Lifesciences, Inc. | DRP-5211-02 | Apr 13, 2032 | |
TorvastatinAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 40's Box of 40's | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | ST. RAPHAEL ARCHANGEL PHARMACEUTICAL PRODUCT DISTRIBUTION | DRP-5880-02 | Sep 9, 2029 | |
TorvastatinAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-6340-02 | Sep 25, 2031 | |
TorvastatinAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-6339-02 | Sep 22, 2031 | |
TorvastatinAtorvastatin (as calcium) | 80 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-6341-02 | Oct 27, 2031 | |
Torzen-40Atorvastatin (as calcium trihydrate) | 40 mg Film-Coated TabletAlu / Alu Blister Pack x 10's (Box of 100’s) | RxVAT-exempt | Healer's Lab (Unit II)India | Hale Medipoint Corp.Importer: Pharmakon Biotec Inc. | DRP-15961-03 | Oct 4, 2029 | |
Torzen-80Atorvastatin (as calcium trihydrate) | 80 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 100’s) | RxVAT-exempt | Healer's Lab (Unit II)India | Hale Medipoint Corp.Importer: Pharmakon Biotec Inc. | DRP-15406-01 | Jul 3, 2029 | |
TrazovastAtorvastatin (as calcium trihydrate) | 80 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 100’s) | RxVAT-exempt | C.B. HEALTHCAREIndia | Pranish Inc. | DR-XY49806 | Sep 24, 2031 | |
TrovipriAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-10746 | Nov 15, 2030 | |
TrovipriAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-10747 | Nov 15, 2031 | |
TrovipriAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-10748 | Nov 15, 2031 | |
TrovipriAtorvastatin (as calcium) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-10749 | Nov 15, 2031 | |
TruvastAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 100's | RxVAT-exempt | Flamingo Pharmaceuticals Ltd.India | Trumed PharmaceuticalsImporter: Hexagon Pharmaceuticals | DRP-2383-01 | May 21, 2029 | |
UnbrandedAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 100's | RxVAT-exempt | Ranbaxy (Malaysia) SDN. BHDMalaysia | Ritemed Phils., Inc. | DRP-1233 | Feb 2, 2029 | |
UnbrandedAtorvastatin (as Calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | TGP Pharma Inc.Importer: Ambica International Corporation | DRP-3123-01 | Jul 12, 2029 | |
UnbrandedAtorvastatin (as Calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Actimed, Inc.Importer: Ambica International Corporation | DRP-3123-03 | Jul 12, 2029 | |
UnbrandedAtorvastatin (As Calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Alkem Laboratories CorporationImporter: Ambica International Corporation | DRP-3123-06 | Jul 12, 2029 | |
UnbrandedAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Actimed, Inc.Trader: Innogen Pharmaceuticals, Inc. | DRP-5614-01 | Mar 19, 2029 | |
UnbrandedAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Dr. Zen’s Research, Inc.Trader: Innogen Pharmaceuticals, Inc. | DRP-5614-04 | Mar 19, 2029 | |
UnbrandedAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 100's | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | Dyna Drug CorporationImporter: AMB HK ENTERPRISES INC. | DRP-11880-02 | May 18, 2032 | |
UnbrandedAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Ranbaxy (Malaysia) SDN. BHDMalaysia | Ritemed Phils., Inc. | DRP-1234 | Feb 2, 2029 | |
UnbrandedAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 24's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Dyna Drug Corporation | DR-XY38470 | Sep 6, 2031 | |
UnbrandedAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | — | DR-XY44901 | Nov 9, 2030 | |
UnbrandedAtorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | TGP Pharma Inc. | DRP-6540-02 | Jul 8, 2029 | |
UnbrandedAtorvastatin (as calcium) | 40 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Ambica International Corporation | DRP-6922 | Nov 22, 2031 | |
Vasator 10Atorvastatin (as Calcium Trihydrate) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's; Box of 100's) | RxVAT-exempt | ACME Formulations Pvt. Ltd.India | GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc. | DRP-12225-03 | Jul 12, 2027 | |
Vascora 20Atorvastatin (as calcium trihydrate) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s, 60's and 100's) | RxVAT-exempt | Pinnacle Life Science Pvt. Ltd.India | Epione Lifecare Inc.Importer: Despina Pharma Inc. | DRP-15744-01 | Sep 11, 2029 | |
Vascora 40Atorvastatin (as calcium trihydrate) | 40mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s, 60’s and 100's) | RxVAT-exempt | Pinnacle Life Science Pvt. Ltd.India | Epione Lifecare Inc.Importer: Despina Pharma Inc. | DRP-15743-01 | Sep 11, 2029 | |
VastaconAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 30's) | RxVAT-exempt | Bal Pharma LimitedIndia | D'Conner PharmaImporter: Pharmakon Biotec Inc. | DRP-5128-03 | Feb 12, 2029 | |
Vastalife-10Atorvastatin (As Calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Life and Health Source Pharmaceutical Distribution Co.Importer: AMB HK Enterprises Inc. | DRP-14015-02 | Jun 6, 2028 | |
Vastalife-20Atorvastatin (As Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Life and Health Source Pharmaceutical Distribution Co.Importer: AMB HK Enterprises Inc. | DRP-14014-02 | Jun 6, 2028 | |
Vastalife-40Atorvastatin (As Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Life and Health Source Pharmaceutical Distribution Co.Importer: AMB HK Enterprises Inc. | DRP-14013-02 | Jun 6, 2028 | |
VastamelAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 40's (Box of 40's, 120's & 200's); Alu/Opaque White PVC Blister Pack x 20's (Box of 100's); Alu/Opaque White PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Amiel Trading Inc. | DRP-5880-06 | Sep 9, 2029 | |
VastamelAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 20's (Box of 100's and 200's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Amiel Trading Inc. | DRP-6340-06 | Oct 7, 2031 | |
VastamelAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's and 200's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Amiel Trading Inc | DRP-6339-06 | Oct 7, 2031 | |
VastamelAtorvastatin (as Calcium) | 80 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's and 200's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Amiel Trading Inc. | DRP-6341-06 | Sep 29, 2031 | |
VastanexAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Medisure Laboratories Pakistan (Pvt.) LimitedPakistan | D'Conner PharmaImporter: Accesspoint International Trading Inc. | DRP-6126-04 | Feb 9, 2037 | |
VASTATORAtorvastatin (as calcium) | 40 mg Film-coated TabletALU / ALU BLISTER PACK X 8'S (BOX OF 40'S) | RxVAT-exempt | J.M. TOLMANN LABORATORIES INC.Philippines | CHMI PHARMA, INC. | DRP-3175-08 | Jan 4, 2030 | |
VASTIRED 80Atorvastatin (as calcium) | 80 mg Film-Coated TabletAlu Foil Strip x 10’s (Box of 100's) | RxVAT-exempt | Sai Parenterals Ltd.#51 TSIIC Industrial Park Hyderabad-Warangal Highway Bhongir Telangana 508116 India | 777 Red Pharma Inc.Importer: Nelpa Lifesciences, Inc. | DRP-10995-02 | Nov 5, 2030 | |
Vastmed 40Atorvastatin (as Calcium Trihydrate) | 40 mg Film-Coated TabletAlu / Alu Blister Pack x 10's (Box of 100’s) | RxVAT-exempt | Healer's Lab (Unit II)India | Northmed Pharma and Medical Supplies DistributionImporter: Pharmakon Biotec Inc. | DRP-15961-04 | Oct 4, 2029 | |
VAZEMIAAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 50's and 100's) | RxVAT-exempt | BIOVEETA LABORATORIES PVT. LTD.India | JAERA PHARMA AND MEDICAL SUPPLIES TRADINGImporter: INTERMAC PHARMACEUTICAL INC. | DRP-5815-03 | Sep 3, 2029 | |
Vazi2rAtorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 40's Box of 40's, 120's & 200's); Alu/Opaque White PVC Blister Pack x 20's Box of 100's; Alu/Opaque White PVC Blister Pack x 10's Box of 30's and 100's | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-5880 | Sep 9, 2029 | |
VAzi2RAtorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 20's (Box of 100's and 200's); Alu/Opaque White PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-6340 | Sep 11, 2030 | |
VAZI2RAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's and 200's); Alu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories, Inc.Philippines | — | DRP-6339 | Sep 11, 2030 | |
Vazi2rAtorvastatin (as calcium) | 80 mg Film-Coated TabletAlu PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories IncPhilippines | — | DRP-16342 | Feb 12, 2030 | |
VAZI2RAtorvastatin (as Calcium) | 80 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's and 200's); Alu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-6341 | Sep 11, 2030 | |
XantorAtorvastatin (as calcium trihydrate) | 10 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 100's) | RxVAT-exempt | Lek S.A.Poland | Importer: Sandoz Philippines Corporation | DRP-15501 | Jul 29, 2029 | |
XantorAtorvastatin (as Calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lek Pharmaceuticals D.D.Slovenia | Importer: Sandoz Philippines Corporation | DRP-2278 | Aug 13, 2029 | |
Xantor: Atorvastatin (as calcium trihydrate) | 20 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 100's) | RxVAT-exempt | Lek S.A.Poland | Importer: Sandoz Philippines Corporation | DRP-15500 | Jul 29, 2029 | |
XantorAtorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 100's | RxVAT-exempt | Lek Pharmaceuticals D.D.Slovenia | Importer: Sandoz Philippines Corporation | DRP-2272 | Jul 3, 2029 | |
XantorAtorvastatin (as calcium trihydrate) | 40 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 100's) | RxVAT-exempt | Lek S.A.Poland | Importer: Sandoz Philippines Corporation | DRP-15499 | Jul 29, 2029 | |
XantorAtorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lek Pharmaceuticals D.D.Slovenia | Importer: Sandoz Philippines Corporation | DRP-2279 | Aug 13, 2029 | |
XantorAtorvastatin (as calcium trihydrate) | 80 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 100's) | RxVAT-exempt | Lek S.A.Poland | Importer: Sandoz Philippines Corporation | DRP-15498 | Jul 29, 2029 | |
XantorAtorvastatin (as Calcium) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lek Pharmaceuticals D.D.Slovenia | Importer: Sandoz Philippines Corporation | DRP-2273 | Aug 13, 2029 | |
XENTORATORVASTATIN ( AS CALCIUM) | 40MG TABLET | RxVAT-exempt | — | Importer: STANGEN PHARMACEUTICALS PHILIPPINES INC | DRP-3517 | Jan 26, 2027 | |
Yorvas-10Atorvastatin (as calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Medisky PharmaceuticalsIndia | Aglobal Care, Inc. | DRP-15640 | Aug 14, 2029 | |
Yorvas-20Atorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Medisky PharmaceuticalsIndia | Aglobal Care, Inc. | DRP-15641 | Aug 14, 2029 | |
Yorvas-40Atorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Medisky PharmaceuticalsIndia | Aglobal Care, Inc. | DRP-15543 | Aug 7, 2029 | |
ZanvatorAtorvastatin (as Calcium Trihydrate) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 100's | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-4295-01 | Mar 13, 2028 | |
Zydusatorva 10Atorvastatin (as Calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's); Alu/Alu Blister Pack x 10's (Box of 10's) as Physician's Sample | RxVAT-exempt | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines Inc. | DRP-12223 | Jun 30, 2032 | |
Zydusatorva 10Atorvastatin (as Calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's); Alu/Alu Blister Pack x 10's (Box of 10's as Physician Sample) | RxVAT-exempt | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines, Inc. | DRP-7597 | Jun 6, 2028 | |
Zydusatorva 20Atorvastatin (As Calcium) | 20 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) Alu/Alu Blister Pack x 10's (Box of 10's) as Physician's Sample | RxVAT-exempt | Cadila Healthcare LimitedIndia | Zydus Healthcare Philippines Inc. | DRP-12222 | Jun 30, 2027 | |
Zydusatorva 80Atorvastatin (as Calcium) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's); Alu/Alu Blister Pack x 8's (Box of 64's); Alu/Alu Blister Pack x 10's (Box of 10's) as Physician's Sample | RxVAT-exempt | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines Inc. | DRP-12154 | Jun 22, 2032 | |
(no brand name)Atorvastatin (as Calcium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack X 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories Inc.Philippines | Trader: Dr. Zen's Research, Inc. | DRP-18263 | Jun 4, 2031 | |
(no brand name)Atorvastatin (As Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack X 10'S | RxVAT-exempt | — | — | DRP-10747-06 | Aug 25, 2037 | |
(no brand name)Atorvastatin (as Calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 3 blister packs x 10 tablets) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-13069 | Nov 24, 2027 | |
(no brand name)Atorvastatin (as calcium) | 20 mg Film-Coated TabletAlu/Alu Blister Pack X 10's (Box of 80's) | RxVAT-exempt | Lloyd Laboratories Inc.Philippines | Trader: Dr. Zen's Research, Inc. | DRP-18264 | Jun 4, 2031 | |
(no brand name)Atorvastatin (as Calcium) | 20 mg Film-Coated TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | Watsons Personal Care Stores (Philippines), Inc.Importer: Philgen Pharmaceuticals Inc. | DRP-2778-04 | Jul 14, 2027 | |
(no brand name)Atorvastatin (as calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 3 blister packs x 10 tablets) | RxVAT-exempt | Stallion Laboratories Pvt., Ltd.India | Ambica International Corporation | DRP-13264 | Jan 18, 2028 | |
(no brand name)Atorvastatin (as Calcium) | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 80's) | RxVAT-exempt | Lloyd Laboratories Inc.Philippines | Trader: Dr. Zen's Research, Inc. | DRP-18316 | Jun 10, 2031 | |
(no brand name)Atorvastatin (As Calcium) | 40mg Film-Coated TabletAlu/Alu Blister Pack x 10's | RxVAT-exempt | — | — | DRP-3109-04 | Jul 12, 2029 | |
(no brand name)Atorvastatin (as Calcium) | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 80's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Dr. Zen'S Research, Inc. | DRP-18265 | Jun 4, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Tablets:
- 10 mg of atorvastatin: white, elliptical, film-coated tablets debossed with “10” on one side and “VLE 155” on the other side
- 20 mg of atorvastatin: white, elliptical, film-coated tablets debossed with “20” on one side and “VLE 156” on the other side
- 40 mg of atorvastatin: white, elliptical, film-coated tablets debossed with “40” on one side and “VLE 157” on the other side
- 80 mg of atorvastatin: white, elliptical, film-coated tablets debossed with “80” on one side and “VLE 158” on the other side Tablets: 10 mg; 20 mg; 40 mg; 80 mg of atorvastatin (3).
Warnings/Precautions
- Myopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher LIPITOR dosage. Discontinue LIPITOR if markedly elevated CK levels occur or myopathy is diagnosed or suspected. Temporarily discontinue LIPITOR in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis. Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing LIPITOR dosage. Instruct patients to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever (2.5, 5.1, 7.1, 8.5, 8.6).
- Immune-Mediated Necrotizing Myopathy (IMNM): Rare reports of IMNM, an autoimmune myopathy, have been reported with statin use. Discontinue LIPITOR if IMNM is suspected (5.2).
- Hepatic Dysfunction: Increases in serum transaminases have occurred, some persistent. Rare reports of fatal and non-fatal hepatic failure have occurred. Consider testing liver enzymes before initiating therapy and as clinically indicated thereafter. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue LIPITOR (5.3).
5.1 Myopathy and Rhabdomyolysis
5.1 Myopathy and Rhabdomyolysis LIPITOR may cause myopathy (muscle pain, tenderness, or weakness associated with elevated creatine kinase [CK]) and rhabdomyolysis. Acute kidney injury secondary to myoglobinuria and rare fatalities have occurred as a result of rhabdomyolysis in patients treated with statins, including LIPITOR.
Risk Factors for Myopathy Risk factors for myopathy include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs (including other lipid-lowering therapies), and higher LIPITOR dosage [see Drug Interactions (7.1) and Use in Specific Populations (8.5, 8.6)]. Steps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis LIPITOR exposure may be increased by drug interactions due to inhibition of cytochrome P450 enzyme 3A4 (CYP3A4) and/or transporters (e.g., breast cancer resistant protein [BCRP], organic anion-transporting polypeptide [OATP1B1/OATP1B3] and P-glycoprotein [P-gp]), resulting in an increased risk of myopathy and rhabdomyolysis.
Concomitant use of cyclosporine, gemfibrozil, tipranavir plus ritonavir, or glecaprevir plus pibrentasvir with LIPITOR is not recommended. LIPITOR dosage modifications are recommended for patients taking certain anti-viral, azole antifungals, or macrolide antibiotic medications [see Dosage and Administration (2.5)]. Cases of myopathy/rhabdomyolysis have been reported with atorvastatin co-administered with lipid modifying doses (>1 gram/day) of niacin, fibrates, colchicine, and ledipasvir plus sofosbuvir [see Adverse Reactions (6.1)].
Consider if the benefit of use of these products outweighs the increased risk of myopathy and rhabdomyolysis [see Drug Interactions (7.1)]. Concomitant intake of large quantities, more than 1.2 liters daily, of grapefruit juice is not recommended in patients taking LIPITOR [see Drug Interactions (7.1)]. Discontinue LIPITOR if markedly elevated CK levels occur or if myopathy is either diagnosed or suspected.
Muscle symptoms and CK elevations may resolve if LIPITOR is discontinued. Temporarily discontinue LIPITOR in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis (e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy).
Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the LIPITOR dosage. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.
5.2 Immune-Mediated Necrotizing Myopathy
5.2 Immune-Mediated Necrotizing Myopathy There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use, including reports of recurrence when the same or a different statin was administered. IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persists despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents.
Additional neuromuscular and serologic testing may be necessary. Treatment with immunosuppressive agents may be required. Discontinue LIPITOR if IMNM is suspected.
5.3 Hepatic Dysfunction
5.3 Hepatic Dysfunction Increases in serum transaminases have been reported with use of LIPITOR [see Adverse Reactions (6.1)]. In most cases, these changes appeared soon after initiation, were transient, were not accompanied by symptoms, and resolved or improved on continued therapy or after a brief interruption in therapy.
Persistent increases to more than three times the ULN in serum transaminases have occurred in approximately 0.7% of patients receiving LIPITOR in clinical trials. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including LIPITOR. Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury [see Use in Specific Populations (8.7)].
Consider liver enzyme testing before LIPITOR initiation and when clinically indicated thereafter. LIPITOR is contraindicated in patients with acute liver failure or decompensated cirrhosis [see Contraindications (4)]. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue LIPITOR.
5.4 Increases in HbA1c and Fasting Serum Glucose Levels
5.4 Increases in HbA1c and Fasting Serum Glucose Levels Increases in HbA1c and fasting serum glucose levels have been reported with statins, including LIPITOR. Optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices.
5.5 Increased Risk of Hemorrhagic Stroke in Patients
5.5 Increased Risk of Hemorrhagic Stroke in Patients on LIPITOR 80 mg with Recent Hemorrhagic Stroke In a post-hoc analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial where 2,365 adult patients, without CHD who had a stroke or TIA within the preceding 6 months, were treated with LIPITOR 80 mg, a higher incidence of hemorrhagic stroke was seen in the LIPITOR 80 mg group compared to placebo (55, 2.3% LIPITOR vs. 33, 1.4% placebo; HR: 1.68, 95% CI: 1.09, 2.59; p=0.0168). The incidence of fatal hemorrhagic stroke was similar across treatment groups (17 vs. 18 for the atorvastatin and placebo groups, respectively).
The incidence of non-fatal hemorrhagic stroke was significantly higher in the LIPITOR group (38, 1.6%) as compared to the placebo group (16, 0.7%). Some baseline characteristics, including hemorrhagic and lacunar stroke on study entry, were associated with a higher incidence of hemorrhagic stroke in the LIPITOR group [see Adverse Reactions (6.1)].
Consider the risk/benefit of use of LIPITOR 80 mg in patients with recent hemorrhagic stroke.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Cyclosporine, gemfibrozil | Avoid | Higher atorvastatin levels or additive myopathy risk. | Combination not recommended. |
| Clarithromycin, itraconazole | Adjust or monitor | Higher atorvastatin levels (CYP3A4/transporter inhibition). | Do not exceed atorvastatin 20 mg; monitor for myopathy. |
| HIV and HCV protease inhibitors (e.g., tipranavir/ritonavir, glecaprevir/pibrentasvir) | Avoid | Large rises in atorvastatin exposure. | Tipranavir/ritonavir and glecaprevir/pibrentasvir: not recommended. Others: dose caps of 20 or 40 mg per the label. |
| Rifampin | Adjust or monitor | May lower atorvastatin levels. | Give at the same time as atorvastatin. |
| Digoxin | Adjust or monitor | May raise digoxin levels. | Monitor digoxin. |
| Colchicine; fibrates (fenofibrate); niacin ≥1 g/day | Adjust or monitor | Myopathy and rhabdomyolysis (higher risk with kidney impairment). | Weigh benefit vs risk; monitor for muscle symptoms, especially at initiation and titration. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewed- See full prescribing information for details regarding concomitant use of LIPITOR with other drugs or grapefruit juice that increase the risk of myopathy and rhabdomyolysis (2.5, 7.1).
- Rifampin: May reduce atorvastatin plasma concentrations. Administer simultaneously with LIPITOR (7.2).
- Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive (7.3).
- Digoxin: May increase digoxin plasma levels; monitor patients appropriately (7.3).
7.1 Drug
7.1 Drug Interactions that may Increase the Risk of Myopathy and Rhabdomyolysis with LIPITOR LIPITOR is a substrate of CYP3A4 and transporters (e.g., OATP1B1/1B3, P-gp, or BCRP). LIPITOR plasma levels can be significantly increased with concomitant administration of inhibitors of CYP3A4 and transporters. Table 2 includes a list of drugs that may increase exposure to LIPITOR and may increase the risk of myopathy and rhabdomyolysis when used concomitantly and instructions for preventing or managing them [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].
Table 2: Drug Interactions that may Increase the Risk of Myopathy and Rhabdomyolysis with LIPITOR Cyclosporine or Gemfibrozil Clinical Impact: Atorvastatin plasma levels were significantly increased with concomitant administration of LIPITOR and cyclosporine, an inhibitor of CYP3A4 and OATP1B1 [see Clinical Pharmacology (12.3)]. Gemfibrozil may cause myopathy when given alone.
The risk of myopathy and rhabdomyolysis is increased with concomitant use of cyclosporine or gemfibrozil with LIPITOR. Intervention: Concomitant use of cyclosporine or gemfibrozil with LIPITOR is not recommended. Anti-Viral Medications Clinical Impact: Atorvastatin plasma levels were significantly increased with concomitant administration of LIPITOR with many anti-viral medications, which are inhibitors of CYP3A4 and/or transporters (e.g., BCRP, OATP1B1/1B3, P-gp, MRP2, and/or OAT2) [see Clinical Pharmacology (12.3)].
Cases of myopathy and rhabdomyolysis have been reported with concomitant use of ledipasvir plus sofosbuvir with LIPITOR. Intervention:
- Concomitant use of tipranavir plus ritonavir or glecaprevir plus pibrentasvir with LIPITOR is not recommended.
- In patients taking lopinavir plus ritonavir, or simeprevir, consider the risk/benefit of concomitant use with atorvastatin.
- In patients taking saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir, elbasvir plus grazoprevir or letermovir, do not exceed LIPITOR 20 mg.
- In patients taking nelfinavir, do not exceed LIPITOR 40 mg [see Dosage and Administration (2.5)].
- Consider the risk/benefit of concomitant use of ledipasvir plus sofosbuvir with LIPITOR.
- Monitor all patients for signs and symptoms of myopathy particularly during initiation of therapy and during upward dose titration of either drug. Examples: Tipranavir plus ritonavir, glecaprevir plus pibrentasvir, lopinavir plus ritonavir, simeprevir, saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir, elbasvir plus grazoprevir, letermovir, nelfinavir, and ledipasvir plus sofosbuvir. Select Azole Antifungals or Macrolide Antibiotics Clinical Impact: Atorvastatin plasma levels were significantly increased with concomitant administration of LIPITOR with select azole antifungals or macrolide antibiotics, due to inhibition of CYP3A4 and/or transporters [see Clinical Pharmacology (12.3)]. Intervention: In patients taking clarithromycin or itraconazole, do not exceed LIPITOR 20 mg [see Dosage and Administration (2.5)]. Consider the risk/benefit of concomitant use of other azole antifungals or macrolide antibiotics with LIPITOR. Monitor all patients for signs and symptoms of myopathy particularly during initiation of therapy and during upward dose titration of either drug. Examples: Erythromycin, clarithromycin, itraconazole, ketoconazole, posaconazole, and voriconazole. Niacin Clinical Impact: Cases of myopathy and rhabdomyolysis have been observed with concomitant use of lipid modifying dosages of niacin (≥1 gram/day niacin) with LIPITOR. Intervention: Consider if the benefit of using lipid modifying dosages of niacin concomitantly with LIPITOR outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy particularly during initiation of therapy and during upward dose titration of either drug. Fibrates (other than Gemfibrozil) Clinical Impact: Fibrates may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of fibrates with LIPITOR. Intervention: Consider if the benefit of using fibrates concomitantly with LIPITOR outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy particularly during initiation of therapy and during upward dose titration of either drug. Colchicine Clinical Impact: Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with LIPITOR. Intervention: Consider the risk/benefit of concomitant use of colchicine with LIPITOR. If concomitant use is decided, monitor patients for signs and symptoms of myopathy particularly during initiation of therapy and during upward dose titration of either drug. Grapefruit Juice Clinical Impact: Grapefruit juice consumption, especially excessive consumption, more than 1.2 liters/daily, can raise the plasma levels of atorvastatin and may increase the risk of myopathy and rhabdomyolysis. Intervention: Avoid intake of large quantities of grapefruit juice, more than 1.2 liters daily, when taking LIPITOR.
7.2 Drug
7.2 Drug Interactions that may Decrease Exposure to LIPITOR Table 3 presents drug interactions that may decrease exposure to LIPITOR and instructions for preventing or managing them. Table 3: Drug Interactions that may Decrease Exposure to LIPITOR Rifampin Clinical Impact: Concomitant administration of LIPITOR with rifampin, an inducer of cytochrome P450 3A4 and inhibitor of OATP1B1, can lead to variable reductions in plasma concentrations of atorvastatin.
Due to the dual interaction mechanism of rifampin, delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations. Intervention: Administer LIPITOR and rifampin simultaneously.
7.3 LIPITOR Effects on Other Drugs
7.3 LIPITOR Effects on Other Drugs Table 4 presents LIPITOR’s effect on other drugs and instructions for preventing or managing them. Table 4: LIPITOR Effects on Other Drugs Oral Contraceptives Clinical Impact: Co-administration of LIPITOR and an oral contraceptive increased plasma concentrations of norethindrone and ethinyl estradiol [see Clinical Pharmacology (12.3)].
Intervention: Consider this when selecting an oral contraceptive for patients taking LIPITOR. Digoxin Clinical Impact: When multiple doses of LIPITOR and digoxin were co-administered, steady state plasma digoxin concentrations increased [see Clinical Pharmacology (12.3)]. Intervention: Monitor patients taking digoxin appropriately.
Drug Interactions Atorvastatin is a substrate of the hepatic transporters, OATP1B1 and OATP1B3 transporter. Metabolites of atorvastatin are substrates of OATP1B1. Atorvastatin is also identified as a substrate of the efflux transporter BCRP, which may limit the intestinal absorption and biliary clearance of atorvastatin.
Table 5: Effect of Co-administered Drugs on the Pharmacokinetics of Atorvastatin Co-administered drug and dosage regimen Atorvastatin Dosage (mg) Ratio of AUC Represents ratio of treatments (co-administered drug plus atorvastatin vs. atorvastatin alone). Ratio of Cmax See Sections 5.1 and 7 for clinical significance. Cyclosporine 5.2 mg/kg/day, stable dose 10 mg QD Once daily for 28 days 8.69 10.66 Tipranavir 500 mg BID Twice daily /ritonavir 200 mg BID, 7 days 10 mg SD Single dosage 9.36 8.58 Glecaprevir 400 mg QD /pibrentasvir 120 mg QD, 7 days 10 mg QD for 7 days 8.28 22.00 Telaprevir 750 mg q8h Every 8 hours, 10 days 20 mg SD 7.88 10.60, The dose of saquinavir plus ritonavir in this study is not the clinically used dose.
The increase in atorvastatin exposure when used clinically is likely to be higher than what was observed in this study. Therefore, caution should be applied and the lowest dose necessary should be used. Saquinavir 400 mg BID /ritonavir 400 mg BID, 15 days 40 mg QD for 4 days 3.93 4.31 Elbasvir 50 mg QD /grazoprevir 200 mg QD, 13 days 10 mg SD 1.94 4.34 Simeprevir 150 mg QD, 10 days 40 mg SD 2.12 1.70 Clarithromycin 500 mg BID, 9 days 80 mg QD for 8 days 4.54 5.38 Darunavir 300 mg BID /ritonavir 100 mg BID, 9 days 10 mg QD for 4 days 3.45 2.25 Itraconazole 200 mg QD, 4 days 40 mg SD 3.32 1.20 Letermovir 480 mg QD, 10 days 20 mg SD 3.29 2.17 Fosamprenavir 700 mg BID /ritonavir 100 mg BID, 14 days 10 mg QD for 4 days 2.53 2.84 Fosamprenavir 1400 mg BID, 14 days 10 mg QD for 4 days 2.30 4.04 Nelfinavir 1250 mg BID, 14 days 10 mg QD for 28 days 1.74 2.22 Grapefruit Juice, 240 mL QD, Greater increases in AUC (ratio of AUC up to 2.5) and/or Cmax (ratio of Cmax up to 1.71) have been reported with excessive grapefruit consumption (≥ 750 mL-1.2 liters per day). 40 mg SD 1.37 1.16 Diltiazem 240 mg QD, 28 days 40 mg SD 1.51 1.00 Erythromycin 500 mg QID Four times daily, 7 days 10 mg SD 1.33 1.38 Amlodipine 10 mg, single dose 80 mg SD 1.18 0.91 Cimetidine 300 mg QID, 2 weeks 10 mg QD for 2 weeks 1.00 0.89 Colestipol 10 g BID, 24 weeks 40 mg QD for 8 weeks NA 0.74 Ratio based on a single sample taken 8-16 h post dose.
Maalox TC ® 30 mL QID, 17 days 10 mg QD for 15 days 0.66 0.67 Efavirenz 600 mg QD, 14 days 10 mg for 3 days 0.59 1.01 Rifampin 600 mg QD, 7 days (co‑administered) Due to the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations. 40 mg SD 1.12 2.90 Rifampin 600 mg QD, 5 days (doses separated) 40 mg SD 0.20 0.60 Gemfibrozil 600 mg BID, 7 days 40 mg SD 1.35 1.00 Fenofibrate 160 mg QD, 7 days 40 mg SD 1.03 1.02 Boceprevir 800 mg TID Three times daily, 7 days 40 mg SD 2.32 2.66 Table 6: Effect of Atorvastatin on the Pharmacokinetics of Co-administered Drugs Atorvastatin Co-administered drug and dosage regimen Drug/Dosage (mg) Ratio of AUC Ratio of Cmax 80 mg QD Once daily for 15 days Antipyrine, 600 mg SD Single dosage 1.03 0.89 80 mg QD for 10 days See Section 7 for clinical significance. Digoxin 0.25 mg QD, 20 days 1.15 1.20 40 mg QD for 22 days Oral contraceptive QD, 2 months - norethindrone 1 mg - ethinyl estradiol 35 µg 1.28 1.19 1.23 1.30 10 mg SD Tipranavir 500 mg BID Twice daily /ritonavir 200 mg BID, 7 days 1.08 0.96 10 mg QD for 4 days Fosamprenavir 1400 mg BID, 14 days 0.73 0.82 10 mg QD for 4 days Fosamprenavir 700 mg BID /ritonavir 100 mg BID, 14 days 0.99 0.94 LIPITOR had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Drug Interactions Atorvastatin is a substrate of the hepatic transporters, OATP1B1 and OATP1B3 transporter.
Metabolites of atorvastatin are substrates of OATP1B1.
Atorvastatin is also identified as a substrate of the efflux transporter BCRP, which may limit the intestinal absorption and biliary clearance of atorvastatin.
Administer simultaneously with LIPITOR ( 7.2 ). • Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.3 ). • Digoxin: May increase digoxin plasma levels; monitor patients appropriately ( 7.3 ). 7.1 Drug Interactions that may Increase the Risk of Myopathy and Rhabdomyolysis with LIPITOR LIPITOR is a substrate of CYP3A4 and transporters (e.g., OATP1B1/1B3, P-gp, or BCRP).
LIPITOR plasma levels can be significantly increased with concomitant administration of inhibitors of CYP3A4 and transporters.
Table 2: Drug Interactions that may Increase the Risk of Myopathy and Rhabdomyolysis with LIPITOR Cyclosporine or Gemfibrozil Clinical Impact: Atorvastatin plasma levels were significantly increased with concomitant administration of LIPITOR and cyclosporine, an inhibitor of CYP3A4 and OATP1B1 [see Clinical Pharmacology (12.3) ] .
Anti-Viral Medications Clinical Impact: Atorvastatin plasma levels were significantly increased with concomitant administration of LIPITOR with many anti-viral medications, which are inhibitors of CYP3A4 and/or transporters (e.g., BCRP, OATP1B1/1B3, P-gp, MRP2, and/or OAT2) [see Clinical Pharmacology (12.3) ] .
Select Azole Antifungals or Macrolide Antibiotics Clinical Impact: Atorvastatin plasma levels were significantly increased with concomitant administration of LIPITOR with select azole antifungals or macrolide antibiotics, due to inhibition of CYP3A4 and/or transporters [see Clinical Pharmacology (12.3) ] .
Adverse reactions
Common
- Nasopharyngitis (8.3%)
- Arthralgia (6.9%)
- Diarrhea (6.8%)
- Pain in extremity (6.0%)
- Urinary tract infection (5.7%)
- Dyspepsia (4.7%)
- Nausea (4.0%)
Serious
- Myopathy and rhabdomyolysis
- Immune-mediated necrotizing myopathy
- Hepatic dysfunction
- Rises in HbA1c and fasting glucose
- Hemorrhagic stroke risk with 80 mg after recent stroke or TIA
The following important adverse reactions are described below and elsewhere in the labeling:
- Myopathy and Rhabdomyolysis [see Warnings and Precautions (5.1)]
- Immune-Mediated Necrotizing Myopathy [see Warnings and Precautions (5.2)]
- Hepatic Dysfunction [see Warnings and Precautions (5.3)]
- Increases in HbA1c and Fasting Serum Glucose Levels [see Warnings and Precautions (5.4)] Most common adverse reactions (incidence ≥5%) are nasopharyngitis, arthralgia, diarrhea, pain in extremity, and urinary tract infection (6.1). To report SUSPECTED ADVERSE REACTIONS, contact Viatris at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In the LIPITOR placebo-controlled clinical trial database of 16,066 patients (8755 LIPITOR vs. 7,311 placebo; age range 10-93 years, 39% female, 91% White, 3% Black or African American, 2% Asian, 4% other) with a median treatment duration of 53 weeks, the most common adverse reactions in patients treated with LIPITOR that led to treatment discontinuation and occurred at a rate greater than placebo were: myalgia (0.7%), diarrhea (0.5%), nausea (0.4%), alanine aminotransferase increase (0.4%), and hepatic enzyme increase (0.4%).
Table 1 summarizes adverse reactions reported in ≥ 2% and at a rate greater than placebo in patients treated with LIPITOR (n=8,755), from seventeen placebo-controlled trials. Table 1: Adverse Reactions Occurring in ≥ 2% in Patients LIPITOR-Treated with any Dose and Greater than Placebo Adverse Reaction % Placebo N=7,311 % 10 mg N=3,908 % 20 mg N=188 % 40 mg N=604 % 80 mg N=4,055 % Any dose N=8,755 Nasopharyngitis 8.2 12.9 5.3 7.0 4.2 8.3 Arthralgia 6.5 8.9 11.7 10.6 4.3
6.9 Diarrhea 6
6.9 Diarrhea 6.3 7.3 6.4 14.1 5.2
6.8 Pain
6.8 Pain in extremity 5.9 8.5 3.7 9.3 3.1
6.0 Urinary
6.0 Urinary tract infection 5.6 6.9 6.4 8.0 4.1 5.7 Dyspepsia 4.3 5.9 3.2 6.0 3.3 4.7 Nausea 3.5 3.7 3.7 7.1 3.8 4.0 Musculoskeletal pain 3.6 5.2 3.2 5.1 2.3 3.8 Muscle spasms 3.0 4.6 4.8 5.1 2.4 3.6 Myalgia 3.1 3.6 5.9 8.4 2.7 3.5 Insomnia 2.9 2.8 1.1 5.3 2.8 3.0 Pharyngolaryngeal pain 2.1 3.9 1.6 2.8 0.7 2.3 Other adverse reactions reported in placebo-controlled trials include: Body as a Whole: malaise, pyrexia Digestive System: abdominal discomfort, eructation, flatulence, hepatitis, cholestasis Musculoskeletal System: musculoskeletal pain, muscle fatigue, neck pain, joint swelling Metabolic and Nutritional System: transaminases increase, liver function test abnormal, blood alkaline phosphatase increase, creatine phosphokinase increase, hyperglycemia Nervous System: nightmare Respiratory System: epistaxis Skin and Appendages: urticaria Special Senses: vision blurred, tinnitus Urogenital System: white blood cells urine positive Elevations in Liver Enzyme Tests Persistent elevations in serum transaminases, defined as more than 3 times the ULN and occurring on 2 or more occasions, occurred in 0.7% of patients who received LIPITOR in clinical trials. The incidence of these abnormalities was 0.2%, 0.2%, 0.6%, and 2.3% for 10, 20, 40, and 80 mg, respectively.
One patient in clinical trials developed jaundice. Increases in liver enzyme tests in other patients were not associated with jaundice or other clinical signs or symptoms. Upon dose reduction, drug interruption, or discontinuation, transaminase levels returned to or near pretreatment levels without sequelae. Eighteen of 30 patients with persistent liver enzyme elevations continued treatment with a reduced dose of LIPITOR.
Treating to New Targets Study (TNT) In TNT, [see Clinical Studies (14.1)] 10,001 patients (age range 29-78 years, 19% female; 94% White, 3% Black or African American, 1% Asian, 2% other) with clinically evident CHD were treated with LIPITOR 10 mg daily (n=5006) or LIPITOR 80 mg daily (n=4995). In the high-dose LIPITOR group, there were more patients with serious adverse reactions (1.8%) and discontinuations due to adverse reactions (9.9%) as compared to the low-dose group (1.4%; 8.1%, respectively) during a median follow-up of 4.9 years.
Persistent transaminase elevations (≥3 x ULN twice within 4-10 days) occurred in 1.3% of individuals with LIPITOR 80 mg and in 0.2% of individuals with LIPITOR 10 mg. Elevations of CK (≥ 10 x ULN) were higher in the high-dose LIPITOR group (0.3%) compared to the low-dose LIPITOR group (0.1%). Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) In SPARCL, 4,731 patients (age range 21-92 years, 40% female; 93% White, 3% Black or African American, 1% Asian, 3% other) without clinically evident CHD but with a stroke or transient ischemic attack (TIA) within the previous 6 months were treated with LIPITOR 80 mg (n=2365) or placebo (n=2366) for a median follow-up of 4.9 years.
There was a higher incidence of persistent hepatic transaminase elevations (≥ 3 x ULN twice within 4-10 days) in the LIPITOR group (0.9%) compared to placebo (0.1%). Elevations of CK (>10 x ULN) were rare, but were higher in the LIPITOR group (0.1%) compared to placebo (0.0%). Diabetes was reported as an adverse reaction in 6.1% of subjects in the LIPITOR group and 3.8% of subjects in the placebo group.
In a post-hoc analysis, LIPITOR 80 mg reduced the incidence of ischemic stroke (9.2% vs. 11.6%) and increased the incidence of hemorrhagic stroke (2.3% vs. 1.4%) compared to placebo. The incidence of fatal hemorrhagic stroke was similar between groups (17 LIPITOR vs. 18 placebo). The incidence of non-fatal hemorrhagic strokes was significantly greater in the LIPITOR group (38 non-fatal hemorrhagic strokes) as compared to the placebo group (16 non-fatal hemorrhagic strokes).
Patients who entered the trial with a hemorrhagic stroke appeared to be at increased risk for hemorrhagic stroke (16% LIPITOR vs. 4% placebo). Adverse Reactions from Clinical Studies of LIPITOR in Pediatric Patients with HeFH In a 26-week controlled study in pediatric patients with HeFH (ages 10 years to 17 years) (n=140, 31% female; 92% White, 1.6% Black or African American, 1.6% Asian, 4.8% other), the safety and tolerability profile of LIPITOR 10 to 20 mg daily, as an adjunct to diet to reduce total cholesterol, LDL-C, and apo B levels, was generally similar to that of placebo [see Use in Specific Populations (8.4) and Clinical Studies (14.6)].
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of LIPITOR. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Gastrointestinal Disorders: pancreatitis General Disorders: fatigue Hepatobiliary Disorders: fatal and non-fatal hepatic failure Immune System Disorders: anaphylaxis Injury: tendon rupture Musculoskeletal and Connective Tissue Disorders: rhabdomyolysis, myositis.
There have been rare reports of immune-mediated necrotizing myopathy associated with statin use. Nervous System Disorders: dizziness, peripheral neuropathy. There have been rare reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with the use of all statins.
Cognitive impairment was generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks). There have been rare reports of new-onset or exacerbation of myasthenia gravis, including ocular myasthenia, and reports of recurrence when the same or a different statin was administered.
Psychiatric Disorders: depression Respiratory Disorders: interstitial lung disease Skin and Subcutaneous Tissue Disorders: angioneurotic edema, bullous rashes (including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis)
Adverse reaction frequency tables (US label) US FDA label
| Adverse Reaction | % Placebo N=7,311 | % 10 mg N=3,908 | % 20 mg N=188 | % 40 mg N=604 | % 80 mg N=4,055 | % Any dose N=8,755 |
| Nasopharyngitis | 8.2 | 12.9 | 5.3 | 7.0 | 4.2 | 8.3 |
| Arthralgia | 6.5 | 8.9 | 11.7 | 10.6 | 4.3 | 6.9 |
| Diarrhea | 6.3 | 7.3 | 6.4 | 14.1 | 5.2 | 6.8 |
| Pain in extremity | 5.9 | 8.5 | 3.7 | 9.3 | 3.1 | 6.0 |
| Urinary tract infection | 5.6 | 6.9 | 6.4 | 8.0 | 4.1 | 5.7 |
| Dyspepsia | 4.3 | 5.9 | 3.2 | 6.0 | 3.3 | 4.7 |
| Nausea | 3.5 | 3.7 | 3.7 | 7.1 | 3.8 | 4.0 |
| Musculoskeletal pain | 3.6 | 5.2 | 3.2 | 5.1 | 2.3 | 3.8 |
| Muscle spasms | 3.0 | 4.6 | 4.8 | 5.1 | 2.4 | 3.6 |
| Myalgia | 3.1 | 3.6 | 5.9 | 8.4 | 2.7 | 3.5 |
| Insomnia | 2.9 | 2.8 | 1.1 | 5.3 | 2.8 | 3.0 |
| Pharyngolaryngeal pain | 2.1 | 3.9 | 1.6 | 2.8 | 0.7 | 2.3 |
Monitoring parameters
- Muscle symptoms (myopathy, rhabdomyolysis); renal impairment is a risk factor (label). Kidney
- LDL-C as early as 4 weeks after starting or changing the dose
- Muscle symptoms, especially when starting, titrating or adding an interacting drug
- Liver enzymes when clinically indicated
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Discontinue LIPITOR when pregnancy is recognized. Alternatively, consider the ongoing therapeutic needs of the individual patient. LIPITOR decreases synthesis of cholesterol and possibly other biologically active substances derived from cholesterol; therefore, LIPITOR may cause fetal harm when administered to pregnant patients based on the mechanism of action [see Clinical Pharmacology (12.1)].
In addition, treatment of hyperlipidemia is not generally necessary during pregnancy. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hyperlipidemia for most patients. Available data from case series and prospective and retrospective observational cohort studies over decades of use with statins in pregnant women have not identified a drug-associated risk of major congenital malformations.
Published data from prospective and retrospective observational cohort studies with LIPITOR use in pregnant women are insufficient to determine if there is a drug-associated risk of miscarriage (see Data). In animal reproduction studies, no adverse developmental effects were observed in pregnant rats or rabbits orally administered atorvastatin at doses that resulted in up to 30 and 20 times, respectively, the human exposure at the maximum recommended human dose (MRHD) of 80 mg, based on body surface area (mg/m 2).
In rats administered atorvastatin during gestation and lactation, decreased postnatal growth and development delay were observed at doses ≥ 6 times the MRHD (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Data Human Data A Medicaid cohort linkage study of 1,152 statin-exposed pregnant women compared to 886,996 controls did not find a significant teratogenic effect from maternal use of statins in the first trimester of pregnancy, after adjusting for potential confounders – including maternal age, diabetes mellitus, hypertension, obesity, and alcohol and tobacco use – using propensity score-based methods. The relative risk of congenital malformations between the group with statin use and the group with no statin use in the first trimester was 1.07 (95% confidence interval 0.85 to 1.37) after controlling for confounders, particularly pre-existing diabetes mellitus.
There were also no statistically significant increases in any of the organ-specific malformations assessed after accounting for confounders. In the majority of pregnancies, statin treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. Study limitations include reliance on physician coding to define the presence of a malformation, lack of control for certain confounders such as body mass index, use of prescription dispensing as verification for the use of a statin, and lack of information on non-live births.
Animal Data Atorvastatin was administered to pregnant rats and rabbits during organogenesis at oral doses up to 300 mg/kg/day and 100 mg/kg/day, respectively. Atorvastatin was not teratogenic in rats at doses up to 300 mg/kg/day or in rabbits at doses up to 100 mg/kg/day. These doses resulted in multiples of about 30 times (rat) or 20 times (rabbit) the human exposure at the MRHD based on surface area (mg/m2).
In rats, the maternally toxic dose of 300 mg/kg resulted in increased post-implantation loss and decreased fetal body weight. At the maternally toxic doses of 50 and 100 mg/kg/day in rabbits, there was increased post-implantation loss, and at 100 mg/kg/day fetal body weights were decreased. In a study in pregnant rats administered 20, 100, or 225 mg/kg/day from gestation day 7 through to lactation day 20 (weaning), there was decreased survival at birth, postnatal day 4, weaning, and post-weaning in pups of mothers dosed with 225 mg/kg/day, a dose at which maternal toxicity was observed.
Pup body weight was decreased through postnatal day 21 at 100 mg/kg/day, and through postnatal day 91 at 225 mg/kg/day. Pup development was delayed (rotorod performance at 100 mg/kg/day and acoustic startle at 225 mg/kg/day; pinnae detachment and eye-opening at 225 mg/kg/day). These doses correspond to 6 times (100 mg/kg) and 22 times (225 mg/kg) the human exposure at the MRHD, based on AUC.
Atorvastatin crosses the rat placenta and reaches a level in fetal liver equivalent to that of maternal plasma.
Mechanism of action
12.1 Mechanism of Action LIPITOR is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. In animal models, LIPITOR lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; LIPITOR also reduces LDL production and the number of LDL particles.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics LIPITOR, as well as some of its metabolites, are pharmacologically active in humans. The liver is the primary site of action and the principal site of cholesterol synthesis and LDL clearance. Drug dosage, rather than systemic drug concentration, correlates better with LDL-C reduction. Individualization of drug dosage should be based on therapeutic response [see Dosage and Administration (2)].
Pharmacokinetics
Key PK parameters
| Bioavailability | About 14% (parent); about 30% HMG-CoA reductase inhibitory activity |
|---|---|
| Time to peak | 1 to 2 hours |
| Half-life | About 14 hours (inhibitory activity 20 to 30 hours) |
| Half-life in kidney failure (ESKD) kidney | Not studied in ESRD (label). |
| Volume of distribution | About 381 L |
| Protein binding | ≥98% |
| Metabolism (CYP, transporters) | Extensive, CYP3A4; substrate of OATP1B1/1B3, P-gp and BCRP |
| Active metabolites | Ortho- and parahydroxylated metabolites (about 70% of circulating inhibitory activity) |
| Renal excretion kidney | Less than 2% in urine; mainly biliary |
| Dialyzability kidney | Not expected to be significantly removed (highly protein bound; label). |
Excretion LIPITOR and its metabolites are eliminated primarily in bile following hepatic and/or extra-hepatic metabolism; however, the drug does not appear to undergo enterohepatic recirculation.
Mean plasma elimination half-life of LIPITOR in humans is approximately 14 hours, but the half-life of inhibitory activity for HMG-CoA reductase is 20 to 30 hours due to the contribution of active metabolites.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Absorption LIPITOR is rapidly absorbed after oral administration; maximum plasma concentrations occur within 1 to 2 hours. Extent of absorption increases in proportion to LIPITOR dose. The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism. Although food decreases the rate and extent of drug absorption by approximately 25% and 9%, respectively, as assessed by Cmax and AUC, LDL-C reduction is similar whether LIPITOR is given with or without food.
Plasma LIPITOR concentrations are lower (approximately 30% for Cmax and AUC) following evening drug administration compared with morning. However, LDL-C reduction is the same regardless of the time of day of drug administration. Distribution Mean volume of distribution of LIPITOR is approximately 381 liters. LIPITOR is ≥98% bound to plasma proteins.
A blood/plasma ratio of approximately 0.25 indicates poor drug penetration into red blood cells. Elimination Metabolism LIPITOR is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products. In vitro inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of LIPITOR.
Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites. In vitro studies suggest the importance of LIPITOR metabolism by cytochrome P450 3A4, consistent with increased plasma concentrations of LIPITOR in humans following co-administration with erythromycin, a known inhibitor of this isozyme [see Drug Interactions (7.1)].
In animals, the ortho-hydroxy metabolite undergoes further glucuronidation. Excretion LIPITOR and its metabolites are eliminated primarily in bile following hepatic and/or extra-hepatic metabolism; however, the drug does not appear to undergo enterohepatic recirculation. Mean plasma elimination half-life of LIPITOR in humans is approximately 14 hours, but the half-life of inhibitory activity for HMG-CoA reductase is 20 to 30 hours due to the contribution of active metabolites.
Less than 2% of a dose of LIPITOR is recovered in urine following oral administration. Specific Populations Geriatric Plasma concentrations of LIPITOR are higher (approximately 40% for Cmax and 30% for AUC) in healthy elderly subjects (age ≥65 years) than in young adults. Pediatric Apparent oral clearance of atorvastatin in pediatric subjects appeared similar to that of adults when scaled allometrically by body weight as the body weight was the only significant covariate in atorvastatin population PK model with data including pediatric HeFH patients (ages 10 years to 17 years of age, n=29) in an open-label, 8-week study.
Gender Plasma concentrations of LIPITOR in females differ from those in males (approximately 20% higher for Cmax and 10% lower for AUC); however, there is no clinically significant difference in LDL-C reduction with LIPITOR between males and females. Renal Impairment Renal disease has no influence on the plasma concentrations or LDL-C reduction of LIPITOR [see Use in Specific Populations (8.6)].
While studies have not been conducted in patients with end-stage renal disease, hemodialysis is not expected to significantly enhance clearance of LIPITOR since the drug is extensively bound to plasma proteins. Hepatic Impairment In patients with chronic alcoholic liver disease, plasma concentrations of LIPITOR are markedly increased.
Cmax and AUC are each 4-fold greater in patients with Childs-Pugh A disease. Cmax and AUC are approximately 16-fold and 11-fold increased, respectively, in patients with Childs-Pugh B disease [see Use in Specific Populations (8.7)]. Drug Interactions Atorvastatin is a substrate of the hepatic transporters, OATP1B1 and OATP1B3 transporter.
Metabolites of atorvastatin are substrates of OATP1B1. Atorvastatin is also identified as a substrate of the efflux transporter BCRP, which may limit the intestinal absorption and biliary clearance of atorvastatin. Table 5: Effect of Co-administered Drugs on the Pharmacokinetics of Atorvastatin Co-administered drug and dosage regimen Atorvastatin Dosage (mg) Ratio of AUC Represents ratio of treatments (co-administered drug plus atorvastatin vs. atorvastatin alone).
Ratio of Cmax See Sections 5.1 and 7 for clinical significance. Cyclosporine 5.2 mg/kg/day, stable dose 10 mg QD Once daily for 28 days 8.69 10.66 Tipranavir 500 mg BID Twice daily /ritonavir 200 mg BID, 7 days 10 mg SD Single dosage 9.36 8.58 Glecaprevir 400 mg QD /pibrentasvir 120 mg QD, 7 days 10 mg QD for 7 days 8.28 22.00 Telaprevir 750 mg q8h Every 8 hours, 10 days 20 mg SD 7.88 10.60, The dose of saquinavir plus ritonavir in this study is not the clinically used dose.
The increase in atorvastatin exposure when used clinically is likely to be higher than what was observed in this study. Therefore, caution should be applied and the lowest dose necessary should be used. Saquinavir 400 mg BID /ritonavir 400 mg BID, 15 days 40 mg QD for 4 days 3.93 4.31 Elbasvir 50 mg QD /grazoprevir 200 mg QD, 13 days 10 mg SD 1.94 4.34 Simeprevir 150 mg QD, 10 days 40 mg SD 2.12 1.70 Clarithromycin 500 mg BID, 9 days 80 mg QD for 8 days 4.54 5.38 Darunavir 300 mg BID /ritonavir 100 mg BID, 9 days 10 mg QD for 4 days 3.45 2.25 Itraconazole 200 mg QD, 4 days 40 mg SD 3.32 1.20 Letermovir 480 mg QD, 10 days 20 mg SD 3.29 2.17 Fosamprenavir 700 mg BID /ritonavir 100 mg BID, 14 days 10 mg QD for 4 days 2.53 2.84 Fosamprenavir 1400 mg BID, 14 days 10 mg QD for 4 days 2.30 4.04 Nelfinavir 1250 mg BID, 14 days 10 mg QD for 28 days 1.74 2.22 Grapefruit Juice, 240 mL QD, Greater increases in AUC (ratio of AUC up to 2.5) and/or Cmax (ratio of Cmax up to 1.71) have been reported with excessive grapefruit consumption (≥ 750 mL-1.2 liters per day). 40 mg SD 1.37 1.16 Diltiazem 240 mg QD, 28 days 40 mg SD 1.51 1.00 Erythromycin 500 mg QID Four times daily, 7 days 10 mg SD 1.33 1.38 Amlodipine 10 mg, single dose 80 mg SD 1.18 0.91 Cimetidine 300 mg QID, 2 weeks 10 mg QD for 2 weeks 1.00 0.89 Colestipol 10 g BID, 24 weeks 40 mg QD for 8 weeks NA 0.74 Ratio based on a single sample taken 8-16 h post dose.
Maalox TC ® 30 mL QID, 17 days 10 mg QD for 15 days 0.66 0.67 Efavirenz 600 mg QD, 14 days 10 mg for 3 days 0.59 1.01 Rifampin 600 mg QD, 7 days (co‑administered) Due to the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations. 40 mg SD 1.12 2.90 Rifampin 600 mg QD, 5 days (doses separated) 40 mg SD 0.20 0.60 Gemfibrozil 600 mg BID, 7 days 40 mg SD 1.35 1.00 Fenofibrate 160 mg QD, 7 days 40 mg SD 1.03 1.02 Boceprevir 800 mg TID Three times daily, 7 days 40 mg SD 2.32 2.66 Table 6: Effect of Atorvastatin on the Pharmacokinetics of Co-administered Drugs Atorvastatin Co-administered drug and dosage regimen Drug/Dosage (mg) Ratio of AUC Ratio of Cmax 80 mg QD Once daily for 15 days Antipyrine, 600 mg SD Single dosage 1.03 0.89 80 mg QD for 10 days See Section 7 for clinical significance. Digoxin 0.25 mg QD, 20 days 1.15 1.20 40 mg QD for 22 days Oral contraceptive QD, 2 months - norethindrone 1 mg - ethinyl estradiol 35 µg 1.28 1.19 1.23 1.30 10 mg SD Tipranavir 500 mg BID Twice daily /ritonavir 200 mg BID, 7 days 1.08 0.96 10 mg QD for 4 days Fosamprenavir 1400 mg BID, 14 days 0.73 0.82 10 mg QD for 4 days Fosamprenavir 700 mg BID /ritonavir 100 mg BID, 14 days 0.99 0.94 LIPITOR had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Atorvastatin 10 mg Tablet | ₱1.32–₱9.00Reference ₱4.86 | per tablet | DPRI procurement range |
| Atorvastatin 20 mg Tablet | ₱1.00–₱10.61Reference ₱4.98 | per tablet | DPRI procurement range |
| Atorvastatin 40 mg Tablet | ₱1.88–₱19.00Reference ₱9.24 | per tablet | DPRI procurement range |
| Atorvastatin 80 mg Tablet | ₱7.05–₱23.30Reference ₱19.18 | per tablet | DPRI procurement range |
| 10 mg (as calcium) tablet | ₱10.00 | per tablet | PhilHealth GAMOT fixed fee |
| 20 mg (as calcium) tablet | ₱12.25 | per tablet | PhilHealth GAMOT fixed fee |
| 40 mg (as calcium) tablet | ₱17.25 | per tablet | PhilHealth GAMOT fixed fee |
| 80 mg (as calcium) tablet | ₱25.00 | per tablet | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Atorvastatin calcium |
| PNF listing | Oral: 10 mg, 20 mg, 40 mg and 80 mg tablet |
| PhilHealth GAMOT | Yes (listed since July 28, 2025) |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Lipitor · Viatris Specialty LLC [US FDA-approved label, version 8, April 15, 2024]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a60cc18b-0631-4cf0-b021-9f52224ece65
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- Viatris Specialty LLC. (2024). Lipitor (atorvastatin calcium) [Prescribing information; US FDA-approved label, NDA020702, set ID a60cc18b-0631-4cf0-b021-9f52224ece65, version effective April 15, 2024]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a60cc18b-0631-4cf0-b021-9f52224ece65
- Wanner, C., & Tonelli, M. (2014). KDIGO clinical practice guideline for lipid management in CKD: Summary of recommendation statements and clinical approach to the patient. Kidney International, 85(6), 1303–1309. https://doi.org/10.1038/ki.2014.31
- Schwartz, G. J., Muñoz, A., Schneider, M. F., Mak, R. H., Kaskel, F., Warady, B. A., & Furth, S. L. (2009). New equations to estimate GFR in children with CKD. Journal of the American Society of Nephrology, 20(3), 629–637. https://doi.org/10.1681/ASN.2008030287
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026.
Last updated: .

